Express Pharma March 01-15, 2013

I N D I A’ S F O R E M O S T P H A R M A & B I OT E C H P U B L I C AT I O N March 1-15, 2013 ` 40

www.expresspharmaonline.com

FORTNIGHTLY INSIGHT FOR PHARMA PROFESSIONALS

VOL 8 | NO. 9 | PAGES 68

02-04-05-06-67-68.qxd

2/22/2013

2:14 PM

Page 2

G0F

03-Cover_OK VR.qxd

2/22/2013

12:44 PM

Page 3

I N D I A’ S F O R E M O S T P H A R M A & B I OT E C H P U B L I C AT I O N March 1-15, 2013 ` 40

www.expresspharmaonline.com

FORTNIGHTLY INSIGHT FOR PHARMA PROFESSIONALS

VOL 8 | NO.9 | PAGES 68

LAB FURNITURE FLEXIS SERIES

READY FOR THE FUTURE

WWW.LABGUARD.BIZ Call: +91 22 32566371

Would you ever think about packing critical contents not the appropriate way?

Don‘t risk using the next best packing solution for your sensitive pharmaceuticals.

Get more, deeper and exclusive knowledge about GLASS as primary pharmaceutical packaging material.

Meet us at the FIOLAX® Academy.

26.04.2013 The Lalit Hotel | Mumbai Further Information: SCHOTT Glass India Pvt. Ltd. Mr. Santosh Jadhav Dynasty „A“ Wing; 303/304, 3rd Floor Andheri Kurla Road, Andheri(E) 400 059 Mumbai – India Phone +91 (0)22/4094-7012 Fax +91 (0)22/4094-7001 Cell + 91 9702016376 santosh.jadhav@schott.com www.schott.com/fiolax-academy

E|X|P|R|E|S|S

Pharma VOL 8. NO. 9 MARCH 1-15, 2013

Chairman of the Board Viveck Goenka

CONTENTS MANAGEMENT

Editor Viveka Roychowdhury*

Decoding the better half of India PAGE 30

BUREAUS

RESEARCH

Mumbai Sachin Jagdale, Usha Sharma, Raelene Kambli, Lakshmipriya Nair, Sanjiv Das

Research centre to be set up at Heriot-Watt University

Bangalore Neelam M Kachhap

PAGE 33

Insulin-requiring diabetes up in young chil-

Delhi Shalini Gupta

dren: Study

PAGE 34

MARKETING

Oncolytics lung cancer drug shrinks tumours

Deputy General Manager Harit Mohanty

in 95 per cent patients PAGE 35

Senior Manager Rajesh Bhatkal

PHARMA ALLY ‘India is a focus market of high strategic

PRODUCTION

importance for us’

General Manager B R Tipnis

PAGE 36

Metrohm and FOSS enter strategic

Production Manager Bhadresh Valia

alliance

PAGE 37

Asst. Manager - Scheduling & Coordination Arvind Mane

Everything under control in laboratory and

Asst. Art Director Surajit Patro

production

PAGE 38

Influence of cold forming and product geom-

Chief Designer Pravin Temble

etry on the size of cold form blister PAGE 40

Senior Graphic Designer Rushikesh Konka

Thermo Fisher Scientific introduces

Photo Editor Sandeep Patil

new innovatively designed pipetting

Layout Rakesh Sharma

system

P-LIFE

C I R C U L AT I O N Circulation Team Mohan Varadkar Express Pharma Reg. No.MH/MR/SOUTH-77/2013-15 RNI Regn. No.MAHENG/2005/21398 Printed for the proprietors,The Indian Express Limited by Ms.Vaidehi Thakar at The Indian Express Press, Plot No. EL-208, TTC Industrial Area, Mahape, Navi Mumbai 400710 and Published from Express Towers, 2nd Floor, Nariman Point, Mumbai - 400021.

(Editorial & Administra-tive Offices: Express Towers, 1st Floor, Nariman Point, Mumbai - 400021) *Responsible for selection of news under the PRB Act.

PAGE 42

Bhasker Iyer named Divisional Vice President, India for Abbott’s Pharmaceuticals Business PAGE 65 2013 brings positive hope for pharma sector employees

PAGE 66

MARKET Industry unhappy with draft g’lines for traditional knowledge patents

PAGE 18

Aurobindo Pharma receives US FDA approvals PAGE 19 Copyright @ 2011 The Indian Express Ltd. All rights reserved throughout the world. Reproduction in any manner, electronic or otherwise, in whole or in part, without prior written permission is prohibited.

March 1-15, 2013

Sanofi India launches Combiflam Plus

PAGE 20

Pharmexcil to open warehouse facility in Nigeria PAGE 21 Victoria life science cos explore India market

PAGE 24

www.expresspharmaonline.com

EXPRESS PHARMA

11

W

MEN’S DAY SPECIAL

EDITOR’S NOTE

Remembering Nirbhaya …

Last June, a perceptions poll of 370 gender specialists conducted by TrustLaw, a legal news service run by Thomson Reuters Foundation, ranked India as the worst G20 country to be a woman. Six months later, the Nirbhaya case only underlined the same fact.

The good news, if one may call it that, is that Indian women are not the only ones at the receiving end of gender-based discrimination. Commenting on BBC's Delhi correspondent Soutik Biswas's report, 'How India treats its women' filed on December 29, a blogger called Crathiegirl, who describes herself as a “white, commonwealth born, UK res of many years”, says, “You obviously have never lived in a tiny scottish highland village where there exists a frightening tendency toward intolerance of ANYTHING non-white, non-scottish, non-male coming from 'the real locals' toward anyone with the temerity to in-come from further than 20 miles away.

As a white, commonwealth born, UK res of many years I see the evidence of this every day toward myself and others.”

Biswas’ article makes the point that the Nirbhaya incident happened even while 'the leader of the ruling party, the speaker of the lower house of parliament, at least three chief ministers, and a number of sports and business icons are women.'

So if Indian women cannot look to the government to give them the respect and dignity they need, nay, deserve, can corporate India start the process by creating islands of equal opportunity? Our Women's Day special issue took a long hard look and came up with some answers.

Shalini Gupta, our Delhi correspondent, shot a number of queries to HR heads in the industry and on the whole, feels that the life sciences industry is doing a fairly good job on this front. Read her story, 'Empowering women at work” on pages 62-65 of this issue.

12 EXPRESS PHARMA

www.expresspharmaonline.com

On the other hand, Usha Sharma, our Mumbai correspondent, got slightly bitter-sweet responses when she asked if the glass ceiling was a myth or reality (pages 26-29). And rounding up this issue, is a trend story on the 'New Age Nutra Sutra', analysing the re-positioning of certain natural ingredients as health aids for women, spanning puberty to menopause and beyond. (pages 15-16) Society will need to change its mindset to the girl child as well. As always, it pays to catch them young and start the process early. Maybe we can take cues from how other countries are nurturing young girls.

US President Obama's commitment to invest in the science, technology, engineering and math (STEM) fields has spawned initiatives like Rhode Island’s Tech Collective programme known as STEM in the Middle, to encourage girls to engage with STEM interests. Blogging about this initiative, George Goodno, Director of State Policy Communications at industry think tank BIO (and proud father of two daughters) explains how these initiatives hope to increase the ranks of STEMinists, i.e. young women who are interested in the STEM fields. (See blog post at this link:http://bit.ly/VSlwYZ) Can we have similar initiatives in India?

With BIO, womeninbio.org and other global industry fora increasing their engagement within India, I do hope such ventures are on their agenda. Maybe Nidhi Saxena, CEO and Founder of Karmic Lifesciences and Founder President, Women In Bio India could take the first step?

Here's hoping that by March 8 next year, India will have bettered its ranking among G20 countries on the same TrustLaw poll. And hopefully by then, Nirbhaya's case would have reached its logical conclusion. Or is that too much to hope for?

Viveka Roychowdhury viveka.r@expressindia.com

March 1-15, 2013

MARKET

W H AT ’ S INSIDE

THE BUSINESS OF PHARMACEUTICALS

Biocon enhances partnership with Mylan for insulin products PG 18 Sun Pharma and Taro announce termination of proposed transaction PG 19 Sanofi India launches Combiflam Plus PG 20 Pharmexcil to open warehouse facility in Nigeria PG 21 IPM grows at 9.8 per cent in January 2013 PG 22 Victoria life science cos explore India market PG 24 NIPER celebrates Foundation Day PG 24

MANAGEMENT 26 RESEARCH 33 PHARMA ALLY 36 PHARMA LIFE 62 March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

15

M|A|R|K|E|T

W

T

The pharmaceutical industry has progressed a long way from a 'what's sauce for the gander …' attitude when it comes to women's health needs. As summed up by John J Castellani, President and CEO, the Pharmaceutical Research and Manufacturers of America (PhRMA), “Our increasing knowledge of the less obvious differences between men and women is providing great promise for new and better treatments that will benefit both sexes.”

SUHAS WADWALKAR Vice President – Corporate Affairs Premier Nutraceuticals

Rediscovering the importance of certain dietary components in maintaining women’s health has led to the rapid growth of the women health ingredients market

This was in May 2011, when Castellani was releasing a PhRMA report, according to which 851 medicines were in development for diseases that exclusively or disproportionately affect women. The number included 139 for cancers that affect women and 110 for autoimmune diseases, which strike women three times more often than men. The medicines were all either in human clinical trials or were awaiting review by the Food and Drug Administration (FDA).

The discovery that there are possible differences in the ways men and women metabolise certain substances, or react to stress helped researchers understand that treatments for some diseases needed to take this into account.

Besides the findings featured in PhRMA release, various research reports reveal attractive growth rates of the

women-specific segment of the global pharma market.

GBI Research forecasts the women’s health therapeutics market to grow at a Compound Annual Growth Rate (CAGR) of 7.9 per cent between 2010 and 2017 to record a sales value of $24,671 million in 2017.

Similarly, a 2011 report from Business Insights (BI) valued the global women’s health market in 2010 at $23.3 billion, with a CAGR of 4.2 per cent (2005–10). It is forecast to reach $32.8 billion by 2016 at a CAGR of 5.9 per cent (2010–16).

According to the BI report, hormonal contraceptives was the largest selling drug class in 2010 and is projected to reach $15.2 billion by 2016, followed by osteoporosis treatment as the second largest drug class.

The top 10 brands in the women’s health market accounted for 39.5 per cent of total sales in 2010. Seven out of the top 10 brands are forecast to decline during the forecast period due to impending or expired patents.

Within India, CubeX, a division of Sorento Healthcare has recently released a report titled “Decoding the Better Half of India: Mapping the Health and Wellness Opportunity among Indian Women” which aims to understand the Indian woman's health concerns and identifies unmet opportunities in the women health and wellness market. (See page 30 in this issue: Decoding the better half of India).

Broadly speaking, the five rapidly growing segments in the female health market are products dealing with antiaging, reproductive health, tumours as well as dermatological and beauty products, and mental health treatments.

Postmenopausal osteoporosis and menopause are the two

MEN’S DAY SPECIAL

major drivers of the women's health market, according to a GBI Research report, which also points out that the endometriosis market is heavily genericised and lacks an effective and safe option for the treatment of endometriosis.

But even today, safety issues associated with some treatment regimens for these health issues remain a serious concern. For instance, the majority of these diseases are currently served by hormonal therapeutics and as hormones have been shown to be associated with significant safety issues such as risks of breast cancer and cardiovascular disease, the use of hormones has declined. Women are worried about resuming hormonal therapy for the treatment of menopause/osteoporosis and this translates into an unmet need.

Given the safety issues with existing products, pharma companies do seem to have sensed the opportunity to develop drugs with greater safety profiles at more competitive prices. These safety issues are of particular concern when such therapies are being used by pregnant and lactating women, as the unborn/newborn baby will also be adversely affected by such safety issues.

According to the GBI Research report, the women's health therapeutics market R&D pipeline is moderately strong, with the majority of first-in-class drugs in late stages of development. These drugs are expected to drive market revenues and it is expected that, if they are approved and are shown to have better safety profiles, patients will comply with novel therapies. In particular, non-hormones are set to take over the conventional hormone therapeutics market, predicts the report.

New age 'nutras' It is precisely these safety issues which has seen what Suhas Wadwalkar, Vice President – Corporate Affairs, Premier Nutraceuticals calls the “rediscovery” of the importance of certain dietary components in maintaining women’s health. This has in turn led to the rapid growth of women’s health ingredients market.

While the established safety of natural ingredients during pregnancy and lactation gives a special impetus to this category, Wadwalkar also points out that the increasing life span of women translates into a longer menopausal phase, which is another driver for the overall women's health market.

Dietary and nutritional supplements have been part of our lives for at least the last five decades, more as a longingrained habit rather than for any specific health-related benefits.

As Samantha Marie Izzy, Scientist, Supplement Product Development, Nutrilite, puts it, “Nutrition is like an insurance. You are secured when you take nutritional supplements and therefore its a long term investment for healthcare.” Amway India, which recently launched a range of women healthcare products in India, targeted at hair, skin and nail health, iron deficiency and for women experiencing menopause challenges, is but one of the many companies tapping into this market.

The natural ingredient market has evolved beyond the calcium-iron-zinc-multivitamin routine and in fact, Wadwalkar calls these products New Generation Evidence Based Nutraceuticals (NGEBN).

The terminology seems to have been coined with the sole aim of dealing with the scepticism of both consumers

NGEBNs in healthcare ◆ ◆ ◆

Phytoestrogens help decrease the risk of breast cancer, depression and anxiety symptoms, and increase bone health Resveratrol exhibits bone-protective effects in addition to positively affecting the hearts of menopausal women Isoflavones show promise not only in breast health, but in postmenopausal symptoms, too

Besides these, Standardised and branded cranberry extract, Hibiscus safdariffa, D-mannose and some selected probiotics have proven to be effective in maintaining urinary health ◆ Infertility is where the NGEBNs add great value right from treating male subfertility to infertility in women. Folates to fish oil, all have positive impact on a women’s healthy pregnancy and positive infant outcomes. Some amino acids like L-arginine, antioxidants such as Coq-10 and lycopene and minerals like selenium have made headway into this segment ◆ Skin health is being vigorously targeted by new age nutraceuticals like type I collagen peptides and anti-oxidants used for rebuilding collagen and elastin of the skin (Source: Suhas Wadwalkar, Vice President – Corporate Affairs, Premier Nutraceuticals) ◆

16

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

M|A|R|K|E|T

SAMANTHA MARIE IZZY Scientist Supplement Product Development Nutrilite

Nutrition is like an insurance. You are secured when you take nutritional supplements and therefore its a long term investment for healthcare

March 1-15, 2013

W

as well as the medical community, as there did not seem to be any scientific proof of the benefits of such nutraceutical ingredients.

As Wadwalkar avers, if nutraceuticals come armed with robust scientific studies, clinical trial data and standardisation of dosages, they are allowed to make certainhealth claims after regulatory approval. He claims that as newer and more advanced nutraceutical entities from the world over make their appearance, the ethical market is openly welcoming new entrants.

Quoting ORG IMS data, he says nutraceuticals enjoy the support of 70 per cent specialists, with one out of four prescriptions carrying a nutraceutical product.

Learning from the past, when supplements lost out to prescription products as the former did not have the evidence to back them up, Wadwalkar says there is a boom in research and development activities, robust scientific back-up and clinical trial

and validation of new nutraceutical entities, all of which is paving the way for a major growth in the segment, especially in developing countries.

Izzy, for instance, specialises in research and technical evaluation of nutritional supplements designed to maintain optimal health with her primary focus of research for Nutrilite being omega-3 fatty acids, coenzyme Q10, multicarotene and women's health.

It is not difficult to see why pharma companies, faced with depleting research pipelines and revenue dips due to blockbusters losing patent protection, want a slice of the natural ingredients pie.

Within the India market, Sanofi’s acquisition of Universal Medicare's nutraceutical unit in 2011, shoring up its OTC presence in the country, could be see in this light.

Wadwalkar also draws attention to the changing demographics and increasing life span which is creating

www.expresspharmaonline.com

MEN’S DAY SPECIAL

more demand for supportive products for women of all age groups, from puberty to menopause. An increase in disposable incomes and growth in aspirations to lead of better quality of life is also driving the demand for nutraceutical entities proven to add value to a healthy life style.

And regulators too are keeping up with customer demand and market trends.

India has a relatively new regulatory regime under the Food Safety and Standards Authority of India (FSSAI) which monitors the segment.

The FSSAI recently pulled up several well known food companies, (ranging from Maggi multigrain noodles, Top Ramen, Nutrichoice biscuits, Horlicks, Complan, Heartcare biscuits, Bournvita Lil Champs and Pediasure food supplement) asking them to substantiate the health benefit claims made in their advertisements, proving that it is very much on the job. (See link to The Indian Express report dated February 20, 2013: http://www.indian-

express.com/news/foodauthority-crackdown-on-adclaims/910187/) Alluding to the success of companies like Zydus Cadila (which launched Zydus Nutriva in March 2008 with two spearhead brands: GRD and Globac-Z), Sanofi's 2011 buyout of Universal Medicare's OTC nutraceutical unit, Tablets India, as well as his own company, Wadwalkar says that the growth of natural healthcare products for women will attract more players into the segment. He predicts that the next few years will see at least five-six pharma majors introducing a basket of nutraceuticals targeted at women’s health.

The super-segmentation of the nutra market into women-specific nutra ingredients is still a nascent trend in India. Whether these brands are able to capture the imagination of the increasingly empowered bharatiya nari and retain her as a long time customer/consumer, remains to be seen. viveka.r@expressindia.com

EXPRESS PHARMA

17

M|A|R|K|E|T

COMPANY WATCH Industry unhappy with draft g’lines for traditional knowledge patents To submit representation to Indian Patent office before March 15, 2013 Usha Sharma Mumbai n November 8, 2012 Controller General of Patents Designs and Trademarks (CGPDTM) issued draft guidelines for patenting traditional knowledge (TK) and biological material and asked for comments from the industry. In response, industry and academia are working on the draft and targeting to submit their views/suggestions to the Indian Patent Office before March 15, 2013.

Dr Gopakumar G Nair, Chief Executive Officer, Patent Gurukul said, “Two months ago, the patent office had circulated the draft guidelines and asked for comments related to granting of patents on TK and related and biological related applications. To discuss and prepare final representation before submitting

O

it to the Indian Patent office, we organised a brainstorming session recently at Pravin Gandhi College of Law, Mumbai and came up with many different issues and suggestions which we will be including in our representations.”

“After the discussion we will be circulating our views to academia as well as to the industry and after receiving their comments, we will prepare the final representation. We aim to receive their views /suggestions over the next 10-15 days and by mid March submit the final representation from our end,” Nair added.

It has been reported that the Indian Patent Office is granting patents on the use of TK of India, particularly relating to the Ayurveda, Unani and Siddha systems of medicine, etc and patents have been granted on inventions related to biological resources obtained from India without taking adequate care to observe the

mandate of law. This is inspite of the fact that other international patent offices are denying/objecting to the grant of such patents on the basis of prior art evidence retrieved from the Traditional Knowledge Digital Library (TKDL).

Dr DB Anantha Narayana, Chairman of Herbs and Herbal Products Committee of the Scientific Body of Indian Pharmacopoeia Commission said, “Innovation is a very important to promote investments in TK. Currently, investments in these areas are dismally low. If innovations which meet the inventive step criteria are not given protection under patent law, there will be further reduction in research and benefits to consumers as proposed in the draft guidelines.

Hence, to address these issues, industry and academia came together and discussed various topics in the brainstorming session to

identify the areas which need to changed in the guidelines.”

Highlighting the needs of having such sessions, Dr LR Dwivedi, Pravin Gandhi College of Law mentioned, “We are emphasising the importance of existing TK to enable its benefits to reach the masses through the patent system. To address these issues leading scientists, patents professionals and students of law felt that these guidelines are too strict and they came to the conclusion that these are protectionist and do not promote innovation in India.”

He stressed that the demand is not for patenting what is already known but what is invention through application of science and technology.

During the session, various topics were discussed and speakers emphasised that herbal medicines needs more research support from the Government. u.sharma@expressindia.com

Biocon enhances partnership with Mylan for insulin products Mylan and Biocon will share development, capital and certain other costs to bring the products to market iocon has entered into a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialisation of generic versions of its three insulin analog products.

Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus), Lispro (the generic version of Eli Lilly’s Humalog) and Aspart (the generic version of Novo Nordisk’s NovoLog).

Mylan and Biocon will share development, capital and certain other costs to

B

18

EXPRESS PHARMA

bring the products to market.

Mylan will have exclusive commercialisation rights in the US, Canada, Australia, New Zealand, the European Union and the European Free Trade Association countries through a profit share arrangement with Biocon. Mylan will have co-exclusive commercialisation rights with Biocon in certain other markets around the world.

Kiran Mazumdar-Shaw, Chairman and Managing Director, Biocon said, “Mylan is a natural preferred partner for our portfolio of generic insulin analogs and this collaboration further strengthens our existing successful partnership. We are excited to team up with Mylan to be able to cost effectively address the disease and economic burden that diabetes poses to global health. We are confident that

www.expresspharmaonline.com

together we can build a strong global presence in generic Insulin analogs and thereby provide access to affordable therapy options to physicians, healthcare providers and diabetes patients worldwide.”

Heather Bresch, Chief Executive Officer, Mylan commented, “This collaboration builds off of our existing successful partnership for generic biologics with Biocon and brings Mylan a portfolio of high-value insulin analog products. This collaboration further expands and diversifies our pipeline of complex, difficult-to-manufacture products with strong future growth potential. Importantly, we believe we have the opportunity to be one of the first generic entrants in developed markets into the rapidly growing diabetes area, helping to address unmet needs and

reduce the economic burden to those battling the disease and to the global healthcare system.”

Rajiv Malik, President, Mylan added, “Biocon has served as a trusted development partner for the past three years and we are excited about this expanded relationship.

Our thorough review of the development work completed

by Biocon to date on these products gives us great confidence in the company’s capabilities in this area and in the quality and value of this programme. Our confidence in the potential of this programme is supported by our proven ability to drive value from our partnership with Biocon and we believe Mylan is uniquely positioned to work with Biocon to bring these products to market.”

EP News Bureau- Mumbai

March 1-15, 2013

M|A|R|K|E|T

Aurobindo Pharma receives US FDA approvals Pioglitazone and Pioglitazone Hydrochloride + Metformin Hydrochloride tabs are ready for launch urobindo Pharma has received final approvals from the US Food & Drug Administration (US FDA) to manufacture and market Pioglitazone tablets USP 15 mg, 30 mg and 45 mg (ANDA 200268) and its earli-

A

Pioglitazone Hydrochloride + Metformin Hydrochloride tablets, 15 mg(base)/500 mg, 15 mg(base)/850 mg are the generic equivalents of Takeda

Global Research Development Center's Actos tablets 15 mg, 30 mg, 45 mg and Actoplus Met tablets, 15 mg (base)/500 mg, 15 mg (base)/850 mg respectively.

The products are indicated as an adjunct to diet and exer-

cise to improve glycemic control in adults with Type-II diabetes mellitus.

The combined market size of the products is approximately $2.8 billion for the 12 months ending September 2012 according to

IMS. Aurobindo Pharma now has a total of 177 ANDA approvals (152 Final approvals including 2 from Aurolife Pharma and 25 tentative approvals) from US FDA. EP News Bureau – Mumbai

THE COMBINED MARKET SIZE OF THE PRODUCTS IS APPROXIMATELY $2.8 BILLION FOR THE 12 MONTHS ENDING SEPTEMBER 2012 er tentatively approved Pioglitazone Hydrochloride + Metformin Hydrochloride tablets, 15 mg(base)/500 mg and 15 mg(base)/850 mg (ANDA 200823). The products are ready for launch.

Pioglitazone tablets USP 15 mg, 30 mg, 45 mg and

Sun Pharma and Taro announce termination of proposed transaction Termination was in best interest of respective companies and shareholders un Pharmaceutical Industries and Taro Pharmaceutical Industries have mutually agreed to terminate their merger agreement, announced in August 2012. Both Sun Pharma and Taro (at the direction of the Special Committee) agreed that terminating the merger agreement was in the best interest of the respective companies and shareholders.

All shareholders of Taro (other than Sun Pharma and its affiliates) would have received a cash payment of $39.50 per share upon the closing of the merger.

EP News Bureau – Mumbai

S

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

19

M|A|R|K|E|T

Sanofi India launches Combiflam Plus The launch of this new product marks the company’s foray into the OTC headache segment in India anofi India formerly known as Aventis Pharma has recently launched Combiflam Plus,a combination of paracetamol and caffeine. It is a targeted, fast and effective solution for headaches, which is also gentle on the stomach, according to various research studies.

The launch of this new product marks the company’s foray into the OTC headache segment in India.

While announcing the launch, Anindya Chowdhury, Senior Director — Consumer Healthcare, Sanofi India said, “Today’s hectic and stressful lifestyles are impacting the quality of life and productivity of people.”

Data suggests that over 70 per cent of men and women experience an episode of headache every

S

month, and 36 per cent suffer from it weekly, as per reports in GFK Market Research Findings 2012.

Chowdhury added, “We are pleased to introduce Combiflam Plus to our consumers which is a targeted solution for headaches. This

STATEMENT ABOUT OWNERSHIP AND OTHER PARTICULARS OF EXPRESS PHARMA, MUMBAI, AS REQUIRED UNDER RULE 8 OF THE REGISTRATION OF NEWSPAPERS (CENTRAL) RULES, 1956 FORM - IV (SEE RULE 8) 1. Place of Publication 2. Periodicity of its publication 3. Printer's Name Whether citizen of India Address 4. Publisher's Name Whether citizen of India Address 5. Editor's name Whether citizen of India Address 6. Name and address of individuals who own the newspaper AND Shareholders holding more than One per cent of the total capital

: Express Towers, Nariman Point, Mumbai-400 021 : FORTNIGHTLY : MS. VAIDEHI THAKAR : Yes : Express Towers, Nariman Point, Mumbai-400 021 : MS. VAIDEHI THAKAR : Yes : Express Towers, Nariman Point, Mumbai-400 021 : Ms.Viveka Roychowdhury : Yes : Express Towers, Nariman Point, Mumbai-400 021 : The Indian Express Limited Express Towers, Nariman Point, Mumbai 400021 : Indian Express Holdings & Entp Limited Express Towers, Nariman Point, Mumbai 400021 : Mr. Viveck Goenka & Mr. Anant Goenka Express Towers, Nariman Point Mumbai 400021 : Mr. Shekhar Gupta & Mrs. Neelam Jolly C-6/53, Safdarjung Development Area New Delhi 110 016

I, VAIDEHI THAKAR., hereby declare that the particulars given above are true and to the best of my knowledge and belief.

Date : 1/3/2013

20

EXPRESS PHARMA

sd/VAIDEHI THAKAR Publisher

www.expresspharmaonline.com

combination is shown to have 89 per cent incremental analgesic effect (in terms of total pain relief) when compared with paracetamol monotherapy.”

Caffeine has been shown to have a synergistic and well documented adjuvant action

when combined with analgesics (painkillers). Research in the Journal of the American Medical Association (JAMA) shows that adding caffeine to an analgesic for e.g. paracetamol, increases the potency of the analgesic by approximately 40 per cent.

In a first of its kind ‘Pack of 4s’ packaging in the headache category, Combiflam Plus is priced at ` 9.50/-(MRP) and Combiflam Plus will be available in the states of Uttar Pradesh, Maharashtra, Tamil Nadu, West Bengal, Punjab and Haryana.

Combiflam Plus is a line extension of Combiflam, which has been a trusted brand in the Indian pharmaceutical market for over 25 years, and is present in ‘1 in every three households across India, according to Nielsen study on Combiflam Pricing.

EP News Bureau- Mumbai

GGEl launches first generic Atovaquone Proguanil in the UK Launch follows the revocation of the Malarone patent in the High court in the UK lenmark Generics (Europe) Limited (GGEL) has announced the first generic launch of Atovaquone Proguanil in the UK following the revocation of the Malarone patent in the High court in the UK. Judgement has been handed down in the case of GGEL and Generics [UK] Limited t/a Mylan v The Wellcome Foundation & Glaxo Group Limited. The case involved the revocation of Glaxo’s patent for its anti-malarial product Malarone. Following proceedings in the High Court, Justice Arnold revoked Glaxo’s patent on the basis that it was obvious.

Atovaquone Proguanil is indicated for the prophylaxis and treatment of acute, uncomplicated P. falciparum malaria particularly where there is likely to be resist-

G

ance. Based on IMS Health sales data for the 12 month period ending September 2012, Atovaquone Proguanil garnered sales of euro 20.69 million in the UK. GGEL is part of Glenmark Generics. The European arm is headquartered in the UK and operates through its own entities and distribution partners in the UK, Germany, the Netherlands, Denmark, Sweden and Ireland. GGEL has an exciting portfolio of more than 300 marketing authorisations approved in Europe. In addition to these internal filings, GGEL continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

EP News Bureau- Mumbai March 1-15, 2013

M|A|R|K|E|T

Pharmexcil to open warehouse facility in Nigeria To provide subsidised facilities to all its members

Usha Sharma Mumbai n a move to encourage export business of small and medium-sized pharmaceutical companies, Pharmaceuticals Export Promotion Council of India (Pharmexcil) will set up a warehouse facility in Nigeria under the Brand India Pharma campaign. The facility will be designed specifically for APIs, finished pharma products and formulations.

Pharmexcil is targeting to open the new warehouse facility by the end of March or early April 2013. It will

I

provide subsidised rates to its members for renting the facility.

Nipun Jain, SME Panel Chief, Pharmexcil said, “Under the Market Access Initiative (MAI) Scheme, Pharmexcil will set up its first overseas warehouse facility in Nigeria. As per the scheme, for the first three years, we have planned to give 75 per cent, 50 per cent and 33 per cent subsidies respectively.”

Jain while highlighting other aspects said, “We will only provide land and give subsidy on the rent while other aspects like product

registration and approvals will be taken care of by individual companies. This facility will allow them to hire their own mercantile representatives. Certainly, this will help companies for the initial three years. Companies will be able to understand the market in a better way.”

Pharmexcil has already identified the land which is spread across 3000 – 5000 sq ft. This facility will give value addition to all members who choose to avail of this offer.

“We are already in talks with the The National Agency for Food and Drug Administration and Control

(NAFDAC) to reduce the approval time by approximately two to three months.

NAFDAC representatives and the Indian ambassador in Nigeria have already visited the proposed location and have given the necessary approvals. We are hopeful that formalities will be over soon,” said Jain.

“If this model works out properly, then we have plans to build replicas of this in four other countries as well.

We are considering Japan and ASEAN countries for the next warehouse location,” revealed Jain. u.sharma@expressindia.com

Our expertise has been preferred around the world for 35 years.

Become a part of our exciting new growth story by joining the Calyx family.

Calyx has been a preferred CRAMs & API supplier to customers around the world. Now more than ever before, we are dependent on our global professionals to take us to new heights. While our attractive compensation packages are further enhanced by our ESOP and profit-sharing plans, our impending IPO makes t his one of the most exciting times to join the Calyx family. Be a part of our 500+team as we grow in the Anti-Infective/Macrolides, Antitubercular, Anti Malarial, Anti retroviral, Antihistaminic, Antidiabetic, AntiHypertension, AntiOsteoporosis & the CVS/CNC global supply chains. Calyx remains USFDA, EDQM and WHO Geneva approved.

Vice President – Sales (CRAMS - International) M.Sc / B.Sc and MBA (Mktg / Intl. Business) from a reputed institute, with 15 – 20 yrs proven record in CRAMS mainly in US and EU with min.1000 crore organization.

General Manager - Sales (Domestic & International) M.Sc/B.Sc and MBA (Mktg.) with 12 – 15 yrs proven record in marketing and sales of CRAMS, APIs and intermediates with min.1000 crore organization.

General Manager/ Dy. Gen Manager – Purchase (2) M.Sc. / BE.(Chem.) with PGDMM, with 15-18 yrs. in imported RM procurement, vendor development/negotiation, analysis of market intelligence and competitive pricing.

Dy. Gen Manager/ Manager – Purchase Engineering (2) BE(Mech./Elect.) with PGDMM, with 8 -15 yrs. in procurement of high value engineering equipments from Engineering, Chemical and API industries.

Dy. Gen Manager - Finance Analyst MBA (Fin.) from IIMs or reputed institutes / ICWA, with 10 -12 yrs. in Ratio / Profitability / Industry Analysis, Costing, Budgets, Investments, Treasury & Capex monitoring.

Manager/ Executive - R&D/Information Scientist (Dombivli, Mumbai) (2) Ph. D / Post Doc (Org.), with 5– 10 yrs in literature search, route scouting and patents.

General Manager – R&D/Process Development (Dombivli, Mumbai) Ph. D (Tech.) / M.Tech, with 15-20yrs. in Chemical industry, min.7-10 yrs in API. Proven record in process engineering, automation & innovation.

Dy. Gen Managers/ Managers/ Executives – R&D/Process Development (Dombivli, Mumbai) (20) M.Tech./ B.Tech/ M. Sc (Org), with 5 -15 yrs. in Scale up, Projects, Tech. Transfer, Simulation studies in CRAMS/ APIs .

General Manager/ Dy. Gen. Manager – Productivity (Tarapur) M.Tech.(IIT) & MBA, expertise in Six Sigma (Black Belt), TPM, Automation, etc..

Dy. Gen. Manager – Audit Compliance (Tarapur) (2) M.Sc/ B.Tech & MBA, handled customers & regulatory audits, CAPA converting prospects to customers.

etc.. Flair for

Managers/ Assistant Managers/ Executives – Production, (Dombivli & Tarapur) (45) M.Sc.(Org)/ BE/ Dip./ B. Sc (Chem.), with 5 – 12 yrs in a reputed API Company.

General Manager - R&D/Organic Synthesis (Dombivli, Mumbai) Ph. D / Post Doc (Org.), with 15 -20 yrs. in process chemistry with proven capabilities in developing and delivering synthetic molecules.

Dy. Gen Manager – Quality Assurance (Tarapur, Mumbai) M.Sc.(Org./Analy.), with 12 -15 yrs. in QA with expertise in QMS and cGMP.

Asst. Gen Managers / Managers/ Executives - R&D/Organic Synthesis (Dombivli, Mumbai) (28) Ph. D / Post Doc / M.Sc. (Org.), with 5 -15 yrs in leading CRAMS/ APIs projects.

Dy. Gen Manager - Environment, Health & Safety (Dombivli & Tarapur) (2) M.Sc.(Org) / BE (Chem.) with Dip. in Safety, 12 - 15 yrs in API /Chemical Industry, HAZOP, HAZAN studies & ETP management.

Dy. Gen Manager/ Managers/ Executives - R&D/Analytical Development ( Dombivli, Mumbai) (9) Ph. D / M.Sc (Org./Analy.), with 5 -15 yrs in method development of custom synthesis / API Compounds using HPLC, GC-MS, UV, IR, NMR.

Executive – Projects (Civil / Mech. / Elec./ Chem) (Tarapur, Mumbai) (4) BE/Dip.(Civil / Mech. / Elec./ Chem), with 3-6yrs. in new projects in a API Company Manager- Administration (On Contractual terms) Graduation in Management / Law, with 10+ yrs in Corporate Admin.

Interested candidates are requested to e-mail their resume to hrd@calyxindia.com or hrad@calyxindia.com. Visit our 'Job Opportunities' Section at www.calyxindia.com

Calyx Chemicals and Pharmaceuticals Ltd., Andheri (E), Mumbai. Tel. 022- 66077597/8 Fax: 022 - 66466401 Calyx Chemicals and Pharmaceuticals Limited (the “Company”) is proposing to make, subject to receip t o f requisite approvals, market conditions and other consider ations, an Initial Public Offering of its equity shares ( the “IPO") and has filed the Draft Red Herring Prospectus (the “DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of SEBI at www.sebi.gov.in, the website of the BRLMs, i.e. PL Capital Markets Private Limited at www.plindia.com and YES Bank Limited at www.yesbank.in and is also available on the website of the Company at www.calyx-pharma.com. Potential investors should note that investment in equity shares involves a degree of risk. For details, please refer to the DRHP, including the section titled “Risk Factors” of the DRHP. This publicity material does not constitute an offer ofsecurities in any jurisdiction, including the United States of America(“USA”). Securities may not be offered or sold in the USA without registration under the U.S.Securities Act of1933 as amended, or an exemption there from. The Company has not and does not intend to offer any securities to the public in the USA

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

21

M|A|R|K|E|T

GROWTH TRACKER IPM grows at 9.8 per cent in January 2013 From a therapy perspective 11 therapies have outgrown the IPM growth With bonus units at full value Rank CORPORATE

MAT

MAT Jan -13

MTH

IPM

Jan-13

Val (Cr)

MS%

GR%

Val (Cr)

MS%

GR%

69885

100.00

13.9

5751

100.00

9.8

10.3

383

6.67

4.3

Abbott + Abbott HC + Novo

1

1

4730

6.77

Cipla

2

2

3513

5.03

9.6

316

5.50

5.8

Sun Pharma

3

3

3400

4.86

21.9

314

5.46

21.9

Glaxo

4

5

3257

4.66

16.1

247

4.30

8.0

Zydus + Biochem

5

4

3023

4.33

18.8

266

4.63

22.1

Ranbaxy

6

6

2932

4.20

9.5

245

4.26

15.6

Mankind

7

7

2524

3.61

26.0

197

3.43

17.3

Alkem + Cachet + Indchemie

8

8

2365

3.38

14.3

187

3.25

7.9

Pfizer + Wyeth

9

10

2228

3.19

16.1

179

3.12

9.1

Lupin

10

9

2120

3.03

14.3

182

3.16

13.7

Macleods

11

12

1791

2.56

25.9

143

2.48

16.4

Intas

12

11

1684

2.41

18.5

151

2.62

21.3

Aristo

13

16

1623

2.32

12.8

120

2.08

4.1

Emcure + Zuventus

14

13

1585

2.27

13.4

128

2.23

5.7

Sanofi-Aventis + Universal

15

14

1566

2.24

13.2

126

2.19

8.3

Glenmark

16

15

1372

1.96

23.3

122

2.12

15.7

Dr Reddys

17

17

1368

1.96

9.5

112

1.94

5.4

Micro + Bal

18

19

1311

1.88

14.5

109

1.90

2.4

Ipca

19

23

1237

1.77

17.4

96

1.67

11.3

USV

20

18

1217

1.74

23.6

110

1.91

24.9

he Indian Pharma Market (IPM) grew at 9.8 per cent for the month of January 2013 and was valued at ` 5545 crores.

For the month of January 2013, amongst the top 10, Zydus clocked a growth of 22.1 per cent, Sun Pharma 21.9 per cent and Mankind 17.3 per cent. Five companies have crossed the growth of IPM for the month of January 2013. Without bonus Sun Pharma is ranked at second for the month and MAT for January 2013.

Zydus has improved one rank over last month to be at number four on monthly basis.

Fourrts (India) Laboratories has entered the top 50 corporates.

Amongst the top 50 corporates, the top three corporates in terms of growths are Bharat Serums has the highest growth at 35.6 per cent, USV at 24.9 per cent followed by Zydus at 22.1 per cent.

From a therapy perspective, 11 therapies have outgrown the IPM growth. The anti-infective market has a growth of 6.9 per cent whereas respiratory market is at 6.2 per cent growth. The anti-diabetic market grows at 15.6 per cent and cardiac at 14.5 per cent in chronic business.

T

About PharmaTrac Val in Crs

22

SUPER GROUP

MAT Jan 13

GR%

Mth Jan 13

GR%

IPM

69885

13.9

5751

9.8

ANTI-INFECTIVES

12453

11.6

974

6.9

CARDIAC

8584

17.0

765

14.5

GASTRO INTESTINAL

8017

15.3

622

10.1

VITAMINS / MINERALS / NUTRIENTS

6176

15.4

471

8.9

RESPIRATORY

5316

10.0

493

6.2

PAIN / ANALGESICS

5184

10.3

409

7.0

GYNAECOLOGICAL

4571

10.6

389

11.5

ANTI DIABETIC

4529

19.7

400

15.6

NEURO / CNS

4247

13.3

370

12.9

DERMA

3688

15.4

300

10.1

OPHTHAL / OTOLOGICALS

1248

14.4

101

12.3

HORMONES

1186

18.8

98

11.9

OTHERS

935

17.1

78

15.0

BLOOD RELATED

867

13.2

68

4.9

VACCINES

866

10.8

68

-4.1

ANTI-NEOPLASTICS

667

9.6

52

-0.2

ANTI MALARIALS

646

17.7

30

-0.6

SEX STIMULANTS / REJUVENATORS

393

20.2

37

16.2

STOMATOLOGICALS

313

14.3

26

11.0

EXPRESS PHARMA

www.expresspharmaonline.com

PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech.

AWACS in AIOCD AWACS stands for Advanced Working, Action & Correction System – reflecting the underlying philosophy behind AIOCD AWACS' research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.

Accurate and faster information flows from the market will help clients grow topline and bottom-line.

Terminologies used MAT – Moving Annual Total MTH – Month Val (Cr) – Value in Crores MS per cent – Market Share in Percentage GR per cent – Growth in percentage For more information, http://www.aiocd.net

visit

March 1-15, 2013

M|A|R|K|E|T

EVENT BRIEF 4th Annual Biosimilars Date: March 6-8, 2013 Venue: Mumbai Summary: With over 100 attendees in 2012, the 4th Annual Biosimilars is all set to be bigger and better with exclusive focus on process development and analytics to suggest best strategies for developing the first commercially successful molecule.

Designed under the guidance of the strategic advisory members, the three-day strategic meet will be a platform to understand practical solutions to minimise the risks associated with the highest spend areas of the biosimilars development cycle.

iPHEX 2013 Date: April 24-26, 2013 Venue: Bombay Exhibition Centre Summary: Pharmexcil has announced the launch of iPHEX

2013, India’s own pharmaceutical show under the support of Ministry of Commerce and Industry, Department of Commerce, and Government of India. Over 400 leading Indian companies are expected to showcase the best of pharma products at the event. iPHEX

2013 will see 5000 business visitors including overseas buyers and drug regulators. Further, the presence of large number of drug regulators from overseas market is expected to help Pharmexcil and its members to promote the quality and affordability aspect as envisaged in

‘Brand India’ pharma campaign.

Contact details: Sanika Patil ProjectManager – iPHEX 2013 Tel: 91.11.23324288 M: 91.9582758812 E-mail: sanika@falcon-mail.com

Contact details: Tel: +91 (0)22 40461466 Email: conferencesindia@ubm.com Website: http://www.biosimilars-india.com/?utm_campaign=MEDIAPARTNER&utm _medium=EVENTLISTING&ut m_source=EXPRESSPHARMA

Global Pharma Regulatory Summit Date: March 11-15, 2013 Venue: Mumbai Summary: 2nd Annual Global Pharma Regulatory Summit will focus on the recent regulatory amendments for 2013.

The conference agenda includes a pre-conference summit on GDUFA, US focused day, EU focused day, ROW focused day and a workshop on eCTD Lifecycle management. Some of the confirmed speakers for this summit include Ashish Kohli - Pfizer UK, Naveen Kumar Jain - Dr Reddy’s, Dr Rajkiran Jain - Zydus Cadila, Dr Hoss Dowlat PharmaBio Consulting, Germany, Jasbir Chohan PEC, UK and many more.

Contact details: Tel: +91 (0)22 40461466 E-mail: conferencesindia@ubm.com Website: http://www.pharmaregulationindia.com/?utm_campaign= MEDIAPARTNER&utm_medium=EVENTLISTING&utm_so urce=EXPRESSPHARMA March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

23

M|A|R|K|E|T

POST EVENTS Victoria life science cos explore India market Members of the delegation to harness synergies between Melbourne’s life sciences infrastructure and India’s capabilities in product improvement

Viveka Roychowdhury Mumbai

Members of the life sciences delegation from Victoria

in early February.

Visiting four cities over two weeks, the delegation also participated at India’s two flagship biotechnology events: Bio Asia in Hyderabad and Bangalore India Bio in Bangalore.

Speaking at an industry meet in Mumbai, Professor Andrew F Wilks, the mission spokesperson and Founder, Chairman and Chief Executive Officer, SYN|thesis med chem said, “The agenda of this trip was to understand the Indian market better.” He sees a complimentary synergy between Melbourne’s strong biotech and life sciences infrastructure, mostly focused on the early stages of drug discovery and India’s proven capabilities

s a percursor to the upcoming Super Trade Mission (STM 2013) hosted by the State Government of Victoria, Australia, representatives of 14 companies comprising the Life Sciences Mission, toured India

A

at the later stages of product improvement.

Speaking about his company’s interest in the India market, Wilks said they offer contract research services, drug discovery expertise and a range of research tools and reagents to the pharma industry. They are looking for partners as well as collaborators providing complementary skill sets. The accent is on early stage drug discovery partnerships, as well as venture capital /angel funding to fuel early stage project pipeline, according to him. They are keen to add an India presence to their operations in China.

Some of the delegates already have strong links with India. For instance, one of the recent projects of CSIRO, a government agency with a $1.2 billion budget, was mAb production for Serum Institute of India and PATH. CSIRO has large interests in materials science and engineering and a strong focus on biotech research in Victoria.

Hydrix, another member of the delegation, develops innovative and advanced biomedical products, instruments and systems, all conforming to CE & FDA Class 1 to Class (high risk). Peter Lewis, Director, Hydrix said that his company is looking to assist Indian companies to develop medical devices for international markets.

An interesting example of the opportunities offered the

Victoria lifesciences cluster came from Muranex, a private biopharma company based out of Melbourne, Australia.

The company is focused on development and commercialisation of innovative products for sepsis and other acute care indications, and was represented by Dr Maurice Fabiani, Chief Executive Officer and Managing Director on this trip.

He spoke about the company's lead therapeutic product, a clinical anti-vascular endothelial growth factor (VEGF) compound which has already been proved to be safe and effective in Phase II clinical studies for cancer.

Muranex is now looking to re-purpose the existing compound for a different therapeutic application (i.e. sepsis). Outlining research from the Beth Israel Deaconess Medical Centre (BIDMC), a teaching and research affiliate of the Harvard Medical School, Fabiani said the product has a robust IP and patent position with a strong market potential He indicated that part of this trip’s agenda was to look for partners to take it through Phase II clinical studies.

Vishal Srivastava, Director, Knoesis Consulting, a business development company assisting biotech companies in Australia and New Zealand, spoke about his company's work with biotech, functional foods and other life science

companies. Srivastava said that his mission on this trip was to understand the biotech industry and R&D environment in India, develop relationships with biotech companies in India and evaluate partnerships to undertake life science/biotechnology projects in India.

Another member of the delegation from Victoria, Korn Technologies, has the capability through academic partners to create gene constructs and evaluate them in non Indica rice strains. Roger Kalla, Founder and Managing Director, Korn Technologies said that his agenda on this trip included shortlisting an Indian R&D partner with capabilities in the field of gene transfer into Indica rice as well as glass house trials of GM plants and field evaluation of genetically modified Indica rice.

Other representatives of the delegation spoke of expanding current partnerships with Indian companies, as well as exploring more opportunities in the Indian market.

STM 2013 will kick off from March 4-15, with around 150 companies from 10 sectors other than lifesciences.

Depending on the interests of individual sectors, the delegation plans to visit Mumbai, Delhi, Bangalore, Hyderabad, Chennai, Kolkata, Ahmedabad and Pune. viveka.r@expressindia.com

NIPER celebrates Foundation Day ational Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Mohali recently celebrated its Foundation Day at NIPER Convention Centre. Shivraj V Patil, Governor of Punjab was the Chief Guest of the programme and DS Kalha, IAS, Secretary, Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, GOI was the Guest of Honour.

Dr KK Bhutani, officiating Director highlighted the activities and performance of NIPER for the previous year.

Patil while congratulating NIPER on its Foundation Day

N

24

EXPRESS PHARMA

(L -R) Prof KK Bhutani Director, NIPER, Shivraj V Patil, Governor, Punjab, DS Kalha, Secretary , Ministry of Chemicals and Fertilizers lauded its achievements in furthering the cause of pharmaceutical sciences in the country. NIPER is the first institute of its kind meant priwww.expresspharmaonline.com

marily to meet the manpower and technology needs of the pharma research industry, he said.

During the second ses-

sion, Dr TS Balganesh, distinguished Scientist, CSIR delivered the Astra Zeneca Oration entitled 'Trials and Tribulations: the challenge of finding new drugs for the treatment of Tuberculosis.'

At the end of the programme, Bhutani distributed prizes to students and staff of the institute for being winners in various events organised earlier. The best scientific support award was presented to Nishi Sharda, the best technical support award to Sandeep Sachdeva and the best administrative support award to Hardip Singh.

EP News Bureau - Mumbai March 1-15, 2013

W H AT ’ S INSIDE

MANAGEMENT INSIGHT FOR MANAGING PHARMA

Decoding the better half of India PG 30

RESEARCH 33 PHARMA ALLY 36 PHARMA LIFE 62 26

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

M|A|N|A|G|E|M|E|N|T

W

MEN’S DAY SPECIAL

Knowledge does not have a gender divide honestly believe that the glass ceiling is a perception and women with talent, determination and conviction can break through it. In my view, being a woman provides us with special attributes such as compassion, sensitivity, multi-tasking, and above all, the inner strength to excel.

With the right mix of skill, experience and resourcefulness, being at the helm as a woman can be one of the most rewarding experiences.

Indian women have come a long way since I started Biocon in the late 70s. At that time women were considered a ‘risk factor’ in business and I faced numerous hurdles because of my gender. No bank wanted to lend me capital and I found it difficult to find people to work for me.

But I persevered as I was

I

KIRAN MAZUMDAR SHAW Chairman and Managing Director Biocon

committed to make a difference and I drew strength from every new challenge posed at me, converting it into a new opportunity.

Today, women get a lot of support from the government as well as from financial institutions, and you see a large

I am proud to be a woman and I strongly believe that the world belongs to those who want to make a difference

number of women in the corporate world as well as successful women entrepreneurs. However, for women to succeed, it is also imperative to have family support and co-operation, especially for balancing home and work life which may become difficult without adequate support from the family. Whilst it is true that I was single when I built Biocon, the real growth came when I got married. My husband has played a vital role in our success today.

I truly believe that knowledge does not have a gender divide - women scientists, women engineers and women writers have enormous opportunities to excel and succeed. Women can use their instincts, intellects, thoughts and ideas to their advantage. Women are good team players and female

bosses often make very democratic leaders. Giving high levels of responsibility is the biggest motivating factor for most. To perform well under this pressure brings in a feeling of great achievement. In today’s global scenario, a sense of self confidence, determination, hard work and business intelligence chart the way to the top. A sense of overall perseverance is very essential.

Over these decades, Indian women have made a mark in diverse fields such as business, the media, financial institutions, and pharmaceuticals through their sheer courage, hard work and conviction.

I am proud to be a woman and strongly believe that the world belongs to those who want to make a difference.

Gender diversity at workplace is key to growth recently read in an article that in life sciences women make up 73 per cent of medical and health services managers, 34 per cent of middle level managers, 17 per cent of top level management and only four per cent of CEOs are women. Companies can address this issue by offering a strong executive mentoring programme and HR policies that offer women the choice to advance their careers and empower them to have a work life balance.

I did not face any specific discrimination. My advice to women at the workplace has always been to be confident and speak up. Most organisations these days have clear guidelines around this.

I

DEEPSHIKHA KIYAWAT Business Unit Director, Specialty, Bristol-Myers Squibb

At Bristol Myers Squibb (BMS), there is a clear focus towards promoting diversity at various levels of the organisation including senior management. The Executive Mentoring Programme along

My advice to women at the workplace has always been to be confident and speak up. Most organisations these days have clear guidelines around this

with other management and leadership training programmes to help women advance and excel in their careers have earned BMS recognition for the 11th year in a row as a 'NAFE Top 50 Company for Executive Women' by the National Association of Female Executives (NAFE). The award recognises the company as a leader in recruiting, retaining and advancing women.

Personally, here in India, diversity is a key enabling strategy for our talent acquisition. We also have the ‘Women in Science’ initiative which provides women a platform to grow and realise their full potential to create value and make a difference

to BMS and its customers globally.

At BMS India we are committed to increase the gender diversity of our workforce. In an initiative led by our Managing Director, Pheroze Khan, BMS India has significantly increased the percentage of women directors in its senior management team.

There are incentives to all business units for increasing the diversity of the sales force. Additionally, the employee referral incentive is higher for the referral of women candidates.

Apart from the mentioned initiatives we also maintain a flexible working environment for pregnant women and new mothers.

Equal opportunities for women in metros am not aware of the exact percentage, however, based on the companies that I know, women at top and senior management positions would be about one per cent and middle management would be in the range of 20 to 35 per cent.

The policy on representation of women at the board level generally depends on the philosophy of each com-

I

FARIDA HUSSAIN President – Marketing USV March 1-15, 2013

Representation of women at the board level depends on the philosophy of each company.

However it should be on the merit of the individual www.expresspharmaonline.com

pany. However, in today's era when women in metro cities are getting equal opportunities, personally I don't think there should be such a policy.

Representation on board should be on the merit of the individual. In the situation of a tie, the individual’s value system, soft skills, passion, commitment and other relevant parameters can be looked at.

EXPRESS PHARMA

27

M|A|N|A|G|E|M|E|N|T

W

MEN’S DAY SPECIAL

Rooting for equal opportunity employers uintiles is an equal opportunities employer and we have a significant percentage of women employees, not only across the organisation, but also in senior positions.

In fact, an analysis of the top 25 organisations that feature in Great Place to Work Institute’s World’s Best Multinational Workplaces 2012, will reveal that Quintiles has the highest percentage of women in executive/senior management at 52 per cent which is significantly higher than most other companies that feature in the listing ( h t t p : / / w w w. g re a t p l a c e t o w o r k . i n / b e s t companies/worlds-best-multi-

Q SUNEELA THATTE Executive Director, Customer Operations Quintiles India

The question should not be whether an organisation has policies for equitable representation of women at the board level as much as whether it is an equal opportunities employer and has policies that foster and encourage women in the workplace

nationals/profiles-of-the-winners/687-23-quintiles).

In India, Quintiles recently received the Highest Percentage of Women Employer-ITES award by the Software Technology Parks of India (STPI), Government of India and the Department of IT, BT and ST, Government of Karnataka for the year 201112. So women are well represented at all levels within our organisation not just in India, but across the globe.

I believe the question should not be whether an organisation has policies for equitable representation of women at the board level as much as whether it is an equal opportunities employer and has policies that foster and encourage women in the

workplace. If an organisation is able to create a womanfriendly work environment and women have a level playing field to further and grow their careers, then it should be on merit and not on gender that should be the determinant of a woman’s climb up the career ladder and whether or not she will occupy a seat at the board.

I believe that senior positions, irrespective of gender, need to be earned and therefore it is important that the culture of the organisation recognises and supports the needs of working women which will create a conducive environment for women to progress their careers and assume senior and board positions.

Gender discrimination exists even today here is no glass ceiling; however, the ascent from middle management to senior management certainly gets tougher for women with drive, ambition and an appetite to take on both internal and external challenges, which include unfair competition from insecure male colleagues and meeting with society’s unrealistic expectations of the perfect home–work life balance.

The more fortunate women, who have apparently succeeded, are those that have a great supportive structure in place by way of friends, colleagues, both male and female at work and a committed family including spouse, children and in laws living the dream with them.

The key driver for success is having the passion for the work you do, being aware of the unique gifts you have been blessed with and the knowledge on how to utilise them to make a difference to as many lives as possible around you.

My passion at PharmaLeaf is international regulatory affairs and the unique gift of being able to connect the in obvious virtual dots across development and commercialisa-

T

SHENAZ Z KHALEELI Co-Founder & Technical Services Director PharmaLeaf India

28

EXPRESS PHARMA

tion in order to advance access to quality safe and cost effective medicines for the global patient.

I have faced gender discrimination in my 24 years of industry experience and am also aware that gender discrimination exists even today, which is worsened by functional discrimination due to varying perceptions in the nature of work where one function is treated differently against another instead of fostering team spirit and establishing joint deliverables for the company. For example the medical function is given more importance than regulatory function and in turn regula-

My strategy is to remain focused on my dreams and stay connected to my close network of family, friends and colleagues in finding creative solutions to move forward, every time I face a new road block

www.expresspharmaonline.com

tory more important than quality assurance, whereas each function has its unique role to play which is interconnected with each other to succeed.

At Pharmaleaf, we work in a virtual, globally networked and harmonised environment, where our priority is to encourage diversity, break away from all discriminations of gender, culture, religion, state etc. and dissolve departmental silos to foster team spirit between global stakeholders collectively responsible for meeting joint project deliverables and timelines.

There have been instances when gender discrimination issues were 'resolved' based on the perceptions and maturity of the decision makers involved.

Yet there were other instances wherein the issues were beyond resolution necessitating one to recognise the politics and hence either flip the page or change the book itself and move on instead of fighting the system.

Every challenging experience makes you a tough professional, resilient and yet positive to be able to cope with changes in life and undoubtedly at work during your tenure in senior management engaging and

mentoring persons from all walks of life.

My strategy is to remain focused on my dreams and stay connected to my close network of family, friends and colleagues in finding creative solutions to move forward, every time I face a new road block.

PharmaLeaf has a NGO partner called Zun Foundation ('Zun' means 'woman' in Persian), with a CSR focus on women and children’s health, education and family welfare. (www.zunfoundation.com) On IWD, PharmaLeaf usually organises activities such as medical camps, well woman talks/presentations sharing useful health information and simple lifestyle tips to the general public to create awareness on the quality of women’s life with topics related to anaemia, reproduction/fertility, cancers, menopause etc.

March 1-15, 2013

M|A|N|A|G|E|M|E|N|T

No real glass ceiling for women

DR JYOTHSNA RAO Research Director, Sri Raghavendra Biotechnologies

think there is no glass ceiling. Women, often take a break in their careers, as a result it gets tougher due to the time lag. Department of Biotechnology/Department of Science and Technology (DBT/DST) has schemes exclusively designed to cater to the immediate needs of women who wish

I

and this is only possible if adequate financial backing is given to qualified entrepreneurs.

I firmly believe that anyone venturing into the life sciences field should have a sound knowledge about the field and this will help in making a success of the enterprise.

Also, understanding the needs of today and to position yourself accordingly will facilitate to maximise profits and break the ceiling.

International Women's Day 2013 is just another day on the calendar. The fact that women and men work together to make a success of their business venture is in itself a celebration.

The fact that women and men work together to make a success of their business venture is in itself a celebration

to re-enter into active research after a break.

In the industry, personally I do not perceive any real blockades/glass ceilings for women as we see many women in higher corporate positions in the life science domain.

Robust schemes for women as soft loans must be granted to enable a women entrepreneur to be able to crystallise their idea into viable business.

I feel that special schemes have to be implemented by financial institutions (both public and private) to enable women to make/build a successful enterprise. India requires more technocrats in the knowledge industry March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

29

M|A|N|A|G|E|M|E|N|T

W

MEN’S DAY SPECIAL

REPORT

Decoding the better half of India Sreedevi Yallamrazu, Sr Strategic Analyst, CubeX - A Division of Sorento Healthcare Communications, highlights the focus areas in the woman’s healthcare market and maps the health and wellness opportunity among Indian women “The truth is, I often like women. I like their unconventionality. I like their completeness. I like their anonymity” —Virginia Woolf t is time to unravel the mystery box called ‘women’.

The fact that the women population is emerging as a force to reckon with – shaping not just their family’s future but the world economy at large, adds relevance in today’s context to Virginia Woolf’s statement about their complete and unconventional side. In the marketing context, it translates to opportunities that women present as ‘consumers’, rather than being mere influencers or decision makers.

Healthcare marketers have been looking at innovative ways and strategies to expand their portfolio. Demographic segmentation has been one of them, especially in case of health supplements. But this strategy is yet to see success in its true sense, especially in case of women.

Taking into account the immense opportunities among ‘women consumers’, CubeX has demystified the Indian woman to understand her as a person - her approach to life, her health concerns and needs in its latest report, ‘Decoding the Better Half of India: Mapping the Health and Wellness Opportunity among Indian Women.’ The opportunity areas have also been charted out for marketers, considering the unmet needs.

The key highlights of the report have been covered in this article.

I

cle in CNN Money. In India itself, the population of women in India aged 12 years and above stands at 440 million (Source: IRS Q1 2012).

Though the urban-rural divide is skewed towards the hinterland, urban women are a key segment for marketers as their exposure to products and evolving trends is much higher and hence, they represent a potential segment. It is noteworthy that the next tier of women too is equally aspirational, though traditional settings may hold them back a bit longer.

Unlike allied industries where Indian marketers are customising male-centric products like automobiles and financial products for women, in healthcare, the mark is yet to be made. The launch of the ‘pill’ 50 years back was heralded as the mightiest weapon a women could have and new launches have focused on better versions of the pill, although women play multifaceted roles and have diverse needs and wants. Women actively seek healthcare information, are often more interested in taking up lifestyle changes for better health outcomes and are open to preventive measures. Women are more likely to self-medicate as they visit the doctor less often

for themselves than for family members. More importantly, as more women become financially independent, they are raising their standard of living and in turn, creating demand for health and wellness products.

More than numbers, women are an integral consumer group today. Women can be a key target audience for digital marketing and also for generating valuable consumer insight, as they use Internet for sharing and gaining opinions from other women. Marketing to women is not limited to facilitating the brand’s purchase. Women are more than consumers. They are willing to explore and can also be brand influencers and advisors.

Defining the new age woman Though women present diverse views and experiences and it may be difficult to club

them into specific groups, they unite in terms of certain common experiences they go through as life progresses.

Women across three age groups – teens, 20+ and 40+ years have been profiled in the report to understand them as a person and specifically their needs. The profile considers various aspects of a woman her thoughts, approach to life and health.

The need for fast pace among teenagers is reflected in their casual attitude towards health matters. While they understand the importance of healthy habits, their inclination to follow them is low, unless it involves enhancing their image. In contrast, young women are concerned about their health, unlike clichéd perceptions and are evidently progressing towards maturity from the rebellious teenage. Although they initially fancy the latest fitness

Women as consumers – The potential Apart from being a purchaser for the family, women are now grouping into key consumer segments themselves across various markets and are slated to assume proportions similar to the current population estimates of India or China, rightly being coined as ‘the third billion’ in an arti-

30

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

M|A|N|A|G|E|M|E|N|T trends, they find them unsustainable, considering their ‘superwoman’ lifestyle and struggle for work-life balance.

They are looking for convenient and time-saving options that will help them to achieve their health goals with ease. Many a time, health eventually takes a back seat among young woman but becomes one of the priorities at menopausal age as health issues start to arise. Curative approach to health issues along with a healthy regimen assumes prime importance among 40+ women. They may seem to slow down, with kids growing up and having achieved a certain status in work, to begin focusing on their own health and wellness.

Each age group has its distinct outlook to health and understanding the key

cern, being prevalent among at least 50 per cent of menstruating women, leaving almost 10 per cent of them incapacitated for one to three days during menses (Source: medindia.net).

In terms of reproductive health, lifestyle changes are leading to hormonal problems and infertility in young women. Almost 35 per cent women in the age group of 20-30 years face Poly Cystic Ovarian Syndrome (PCOS), as cited by online reports, though it is diagnosed only when treatment for infertility is sought.

Assocham surveys have reported that 68 per cent working women suffer from lifestyle diseases like obesity, depression, backache, diabetes and hypertension and an almost equal percentage (age 30-40 years) has symptoms of exhaus-

WOMEN’S HEALTH MARKET IN INDIA IS AT A VERY NASCENT STAGE AND CAPTURES LESS THAN ONE-THIRD SALES OF THE TOTAL INDIAN OTC MARKET ($2 BILLION).WOMEN SPECIFIC HEALTH MARKET HAS SEEN STRONG PRESENCE OF FEW BRANDS SUCH AS I-PILL AND UNWANTED72 IN RECENT TIMES nuances of each group can aid in brand segmentation and targeting strategies.

Understanding women’s health concerns Though women’s health concerns differ in terms of specificity and intensity in different age groups, their key health concerns can be broadly classified into five clusters: general health, reproductive health, feminine intimate care, aches and pain and beauty and wellness.

For example, more than 50 per cent of women across age groups suffer from anaemia, although conspicuously the prevalence is higher in younger age groups (Source: NHFS-3).

The unhealthy diet among urban people and lack of adequate nutrition among poorer socio-economic classes is a major contributor to low BMI levels (normal range 18.5-24.9) among 50 per cent of teenagers (Source: NHFS-3). On the other hand, fast-paced lifestyle, erratic meal schedules and consumption of junk food lead to obesity and micro nutrient deficiencies among young girls.

Among aches and pain, menstrual pain is the chief conMarch 1-15, 2013

tion, irritability and insomnia.

Many women in the age group of 25-40 years have multiple roles to play and in the process of balancing this tight rope walk, they get trapped in the ‘superwoman syndrome’, attracting lifestyle ailments.

As per media reports regarding global estimates of healthy life expectancy (HALE) published in The Lancet, the average life expectancy of women is expected to be 67.5 years, of which the last 10 years are expected to be spent in poor health. As a result of estrogen deficiency beginning with menopause, compounded by lifestyle factors, osteoporosis due to increased bone resorption, hypercholesterolemia due to decreased LDL receptors and atherosclerosis may set in among 40+ women.

Vaginal Yeast Infection (VYI) has been estimated to be on the higher side, given the high prevalence of diabetes, unhygienic sanitary conditions and high birth rate in India.

Sadly, intimate concerns of women are largely unspoken and hence awareness levels are low.

There are 25 health needs which have been identified www.expresspharmaonline.com

EXPRESS PHARMA

31

M|A|N|A|G|E|M|E|N|T

W

across the above five clusters.

Marketers need to broaden their horizon from traditional focus areas of contraception and hormonal replacement therapies to address many other needs of women. It is imperative to show an active interest in understanding them and to engage with them closely to identify their core concerns, rather than simply communicating to them about their needs.

Identifying unmet opportunities in women’s health and wellness Women’s health market in India is at a very nascent stage and captures less than onethird sales of the total Indian OTC market ($2 billion).

Women specific health market has seen strong presence of few brands such as i-pill and Unwanted-72 in recent times.

Brands such as Calcium Sandoz Woman, Revital Woman and Supractiv Complete Woman, which cater to everyday needs and are specifically positioned for women, can drive significant volumes. Among women, decision of consuming supplements is need and evidencebased. Hence, creating awareness regarding preventive health and showcasing brand

E|X|P|R|E|S|S

Pharma HEAD OFFICE MUMBAI Rajesh Bhatkal Business Publications Division, The Indian Express Limited., 1st Floor, Express Towers, Nariman Point, Mumbai-400021. India Tel: 67440503 / 02 Fax: 022-22885831 Mobile: 98213 13017 E-mail : rajesh.bhatkal@expressindia.com Branch Offices NEW DELHI Ambuj Kumar Business Publications Division, The Indian Express Limited, Basement, Express Building, 9 & 10 Bahadur Shah Zafar Marg, New Delhi, 110 002 Direct Line: 011-2346 5727 Board Line: 011-2370 2100-107 Ext-727 Mobile: 09999070900 E-mail: ambuj.kumar@expressindia.com CHENNAI Dr Raghu Pillai The Indian Express Limited, Business Publications Division, New No.37/C (Old No.16/C) 2nd Floor, Whites Road, Royapettah, Chennai - 600 014 Tel: Board: 28543031/28543032/

32

EXPRESS PHARMA

differentiation may create the desired impact. Testimonies of women users or endorsement by female doctors may build confidence as women tend to rely on each other’s advice.

Apart from these brands, most of the other brands have a skew in terms of usage by women. There are many white spaces that currently do not address women’s needs directly through the OTC route. For example, none of the iron supplements are promoted OTC, despite the glaring necessity. Analgesics category are an interesting opportunity area, considering studies that report that women are more sensitive to intense pain than men (Source: Journal of Pain, January 2012). Vaginal yeast infections (VYI) treatments too are still largely prescription-driven or based on home remedies. Introducing effective products in convenient and non-messy formats will drive OTC consumption.

Mild herbal remedies, that can relax the tense muscles and nerves and keep anxiety levels low, would be much welcome by many women.

These areas can open doors to marketers who are looking for new avenues of growth.

Besides, catering to these needs can create first mover

28543033/28543034 Fax: 28543035 E-mail: raghu.pillai@expressindia.com BANGALORE Khaja Ali Business Publications Division, The Indian Express Ltd. 5th Floor, Devatha Plaza 131, Residency RoadBangalore - 560 025, INDIA Tel: 22231923/24/41/60 Fax: 22231925 Cell: 09741100008 E-mail: khaja.ali@expressindia.com HYDERABAD E. Mujahid The Indian Express Ltd. Business Publications Division, 6-3-885/7/B, Ground floor, V.V. Mansion, Somaji Guda, Hyderabad - 500082 Tel: 040 - 23418673/ 23418674/ 66631457 Telefax: 040 - 23418675 Mob: 09849039936 Email: e.mujahid@expressindia.com

advantage.

While new opportunities in the wellness space and feminine intimate care are being explored, existing brands also present greater opportunities which cannot be ignored. Rx to OTC promotional switch of heritage brands such as Dexorange, Shelcal, Lactacyd, Candid and Betadine with women-centric positioning can be excellent growth drivers for these brands, further enhancing their equity. Hence, opportunities are plenty for Rx, OTC and FMHG marketers.

Global inspiration Globally, marketers have tapped into the spectrum of women’s healthcare needs, ranging from head to toe, from cradle to grave, offering products like PMS supplements, antenatal supplements and natural alternatives to hormone replacement therapies for menopausal women. Antifungal brands like Monistat have successfully tapped women from teenage to postmenopause as well as diabetic women, addressing their concerns and fears about VYI. Marketers are also using digital medium to listen and engage women, as they are potential content generators as

2231 8879 / 80 Fax: +91-33-22138582 Cell: 09830130965 / 09831182580 Email: prasenjit.basu@expressindia.com ajanta.sengupta@expressindia.com KOCHI Dr Raghu Pillai Business Publications Division, The Indian Express Limited, Sankoorikal Building, 36/2248, Kaloor,Kadavanthara Road, Opp. Kaloor Private Bus Stand, Kaloor - 682 017 Tel: (0484) 2343152, 2343328 Fax: 2343153 E-mail: Kochi.bpd@expressindia.com raghu.pillai@expressindia.com COIMBATORE The Indian Express Limited, Business Publications Division, st 1 Floor, 731, Avinashi Road, Opp. PRS Grounds, Coimbatore-641 018 Tel: 2212157/2216718/2216732

KOLKATA Prasenjit Basu / Ajanta Sengupta The Indian Express Limited Business Publications Division 5, Pannalal Banerjee Lane (Fancy Lane), 2nd Floor, Kolkata - 700 001 Tel No. (Direct) +91-33-2213 8567 / 8573 Board No. +91-33-2213 8587,

www.expresspharmaonline.com

MEN’S DAY SPECIAL

much as buyers.

It is time to take note of the dual power of women as consumers as well as influencers. Healthcare marketers in India, too, now need to reach out the ‘consumer’ in a woman, focusing on possibilities of a women’s health franchise. Marketing to women has a snow-ball effect even after the purchase, as they become invisible brand ambassadors. Creating a compelling story with an emotional appeal and a rational offering is one of the vital cues in marketing to women. A quote by author, Joannne Yaccato, in the book, The 80% Minority: Reaching the Real World of Women Consumers, succinctly expresses the power of marketing to women consumers, which applies to any product, “If you make it (marketing strategies) woman-friendly, you make it everybody-friendly.”

(CubeX is the Strategic Consulting and Business Intelligence division of Sorento Healthcare Communications with expertise in the Consumer Healthcare and Wellness domain. To know more about reports from CubeX, you can write to reports@cubex.co.in.)

E-mail: bpdcbe@vsnl.in JAIPUR The Indian Express Limited, C-7, Dwarika Puri, Jamna Lal Bajaj Marg, C-Scheme, Jaipur - 302001 Tel: 0141-370002/371272 Telefax: 91-141-376606 BHOPAL The Indian Express Limited, 6, Vidya Vihar, Professors Colony, Bhopal - 462002, Madhya Pradesh Tel: 0755-2661988 AHMEDABAD Rajesh Bhatkal The Indian Express Limited, 3rd Floor, Sambhav House, Nr. Judges Bunglow Bodakdev, Ahmedabad - 380 015.

Tel: (91-79) 26872481 / 82 / 83 Fax: (91-79) 26873950 Mobile: 98213 13017 E-mail : rajesh.bhatkal@expressindia.com

IMPORTANT Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express Limited. cannot be held responsible for such contents, nor for any loss or damages incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or publications.

We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

March 1-15, 2013

RESEARCH

W H AT ’ S INSIDE

EXPERTISE FOR DRUG DEVELOPMENT

UPDATE Research centre to be set up at Heriot-Watt University Will help Scottish scientists to investigate the causes of disease at molecular level new research centre which will help Scottish scientists to investigate the causes of disease at molecular level is to be established at HeriotWatt University, supported by a £2m grant from the Medical Research Council (MRC).

The Edinburgh Super Resolution Imaging Consortium (ESRIC), which will be run in partnership with the Institute of Genetic and Molecular Medicine (IGMM) at the University of Edinburgh, will involve high end equipment, very advanced microscopes which will be able to look at single molecules within live cells at a resolution of five nanometres. This will revolutionise the understanding

A

of cell biology by directly examining the molecular workings of cells. Professor Rory Duncan, Head of the Institute of Biological Chemistry, Biophysics and Bioengineering (IB3) at Heriot-Watt, said, "If we can understand how the molecules work within living cells then we can understand how the cells work.

Every disease is the result of some dysfunction in the way that molecules work or interact within cells, and this is a way to understand the causes of disease at their most basic levels, and hopefully to working out how to prevent and cure those diseases. This is a unique and unparalleled UK resource, and one which we believe

will help researchers to move to the next stage of understanding the causes and potential cure of a wide range of diseases by determining the fundamentals underlying them." The new Consortium will provide equipment and training, technological support and research funding for this new field of study, which demands a new breed of biologists able to work at the interfaces with mathematics, physics and chemistry. This, says Professor Duncan, means that HeriotWatt is ideally placed to host the new Centre. "HeriotWatt University is well known internationally for its work in the physical sciences and in 2010 established the Life Science Interface Laboratory (LSI) to promote and develop life science interfaces with

mathematics, physics and chemistry. This highly successful activity led to the formation of IB3, a biologyled institute designed to accelerate the interactions between disciplines. This interdisciplinary approach means that Heriot-Watt has the academic strengths necessary to support the new facility and to drive its development.” Nick Hastie, Director of the Institute of Genetics and Molecular Medicine, said, “I could not be more excited about this new Imaging Centre which will take our science to a new dimension. This will provide unparalleled opportunities for the biomedical scientists in our Institute to benefit from interactions with the engineers, mathematicians and physicists at Heriot-Watt University.”

EP News Bureau-Mumbai

Insulin-requiring diabetes up in young children: Study PG 34 Oncolytics lung cancer drug shrinks tumours in 95 per cent patients PG 35

Schizophrenia genes increase chance of IQ loss: Study Researchers used latest genetic analysis techniques to reach their conclusion eople who are at greater genetic risk of schizophrenia are more likely to see a fall in IQ as they age, even if they do not develop the condition. Scientists at the University of Edinburgh say the findings could lead to new research into how different genes for schizophrenia affect brain function over time. They also show that genes associated with schizophrenia influence people in other important ways besides causing the illness itself. The researchers used the latest genetic analysis techniques to reach their conclusion on how thinking skills change with age. They compared the IQ scores of more than 1,000

P

March 1-15, 2013

people from Edinburgh who were tested for general cognitive functions in 1947, when the subjects were aged 11, and again when they were around 70 years old.

The researchers were able to examine people’s genes and calculate each subject’s genetic likelihood of developing schizophrenia, even though none of the group had ever developed the illness.

They then compared the IQ scores of people with a high and low risk of developing schizophrenia. They found that there was no difference at age 11, but people with a greater genetic risk of schizophrenia had slightly lower IQs at age 70. Those people who

had more genes linked to schizophrenia also had a greater estimated fall in IQ over their lifetime than those at lower risk.

Ian Deary, Director of the University of Edinburgh’s Centre for Cognitive Ageing and Cognitive Epidemiology, who led the research team, said, “Retaining our thinking skills as we grow older is important for living well and independently. If nature has loaded a person’s genes towards schizophrenia, then there is a slight but detectable worsening in cognitive functions between childhood and old age.” Andrew McIntosh, of the University of Edinburgh’s Centre for Clinical Brain Sciences, said, “With further research into how these genes affect the brain, it could become possiwww.expresspharmaonline.com

ble to understand how genes linked to schizophrenia affect people’s cognitive functions as they age.”

Schizophrenia – a severe mental disorder characterised by delusions and by hallucinations – is in part caused by genetic factors. It affects around 1 per cent of the population, often in the teenage or early adult years, and is associated with problems in mental ability and memory.

The study, which was funded by the BBSRC, Age UK, and the Chief Scientist Office, is published in the journal Biological Psychiatry. The University of Edinburgh’s Centre for Cognitive Ageing and Cognitive Epidemiology is funded by the Cross Council Lifelong Health and Wellbeing initiative.

EP News Bureau-Mumbai

PHARMA ALLY 36 PHARMA LIFE 62 EXPRESS PHARMA

33

R|E|S|E|A|R|C|H

Insulin-requiring diabetes up in young children: Study The number of diagnosed cases among all children up to age 14 rose by 29 per cent he number of cases of insulin-requiring Type-I diabetes rose sharply in children under the age of five in Philadelphia over a two decade span, paralleling increases seen across the US and in Europe, according to a US study. Researchers whose work appeared in the journal Diabetes Care found that the number of Philadelphia children under five diagnosed with Type-I diabetes increased 70 per cent in 2005 from 1985, when a registry of such patients was begun.

The number of diagnosed cases among all children up to age 14 rose by 29 per cent.

"Why are we seeing this large increase in type 1 diabetes in very young children?

Unfortunately, the answer is we don't know," said lead author Terri Lipman, a professor at the University of Pennsylvania School of Nursing. Of the two most common forms of diabetes, Type-II typically affects adults who can still produce insulin, but whose bodies cannot use the hormone to regulate blood sugar.

Type-I, previously known as juvenile diabetes,

T

typically strikes children whose immune systems have killed off insulin-producing cells in the pancreas. The disease is usually fatal if left untreated.

In 1985, according to a registry of Philadelphia children diagnosed with Type-I diabetes, 13.4 out of every 100,000 children in Philadelphia was newly diagnosed with the disease. In 2004, the rate was 17.2 cases per 100,000. Type-I diabetics must take insulin, but many Type-II diabetics can control

the disease with medications, diet and exercise. Type-I diabetes tends to start in adolescence, but experts said parents need to be aware that toddlers and preschoolers are also susceptible, given the rising number of cases in very small children. Children from Chicago to Colorado to Finland have similarly increased rates of Type-I diabetes, though the cause eludes researchers.

“This young group is a mystery,” said Carol Levy, a Type-I diabetes specialist at Mount Sinai Hospital in New

York who was not involved in the study. “Make sure the children has a healthy lifestyle and maintains normal body weight, whether that's a guarantee we're going to reduce risk, we don't know at this point. Several theories vie to explain the recent rise in diabetes among youth, including vitamin D deficiencies, lack of breastfeeding and over-hygienic environments that might cause the immune system to backfire. “The data is controversial, so that's why I'm certainly very reluctant to propose a theory when nothing has been proven,” Lipman said. It is important to be aware of the symptoms of diabetes, which can include extreme thirst, bed wetting or accidents in toilettrained children or excessively wet diapers in babies, said Lori Laffel, Joslin Diabetes Center in Boston. By the time the disease is diagnosed, many infants and toddlers are very sick and the degree of illness tends to be more severe the younger the patient, experts noted. “The young child isn't able to talk about symptoms,” Laffel said. “A young child may be in diapers, you may not notice because diapers are often wet”.

Reuters

GSK wins priority status for new HIV drug in US The once-daily drug, which belongs to a novel class known as integrase inhibitors is owned by ViiV Healthcare London S regulators gave priority review status to an experimental GlaxoSmithKline drug for HIV/AIDS, which industry analysts view as a possible multibillion-dollar-a-year seller. The US Food and

U

Drug Administration awards certain drugs priority status when they have the potential to offer significant improvement over existing treatments. The agency is due to give its verdict on whether to approve dolutegravir by August 17, Britain's biggest drugmaker said.

The once-daily drug, which belongs to a novel class known as integrase inhibitors that block the

virus causing AIDS from entering cells, is owned by ViiV Healthcare, a joint venture focused on HIV in which GSK is the largest shareholder. The new medicine has already performed strongly in clinical trials, prompting GSK to raise its bet on the product last October by redrawing a deal with Japan's Shionogi. Under that agreement Shionogi agreed to take a 10 per cent

stake in Viiv, which was set up in 2009 between GSK and Pfizer in exchange for its shared rights to dolutegravir.

The agreement left GSK holding 76.5 per cent of ViiV, with Pfizer controlling 13.5 per cent and Shionogi the remainder. Analysts see dolutegravir as a strong competitor to HIV treatments from market leader Gilead Sciences.

Reuters

Ablynx books success with arthritis drug study Ablynx had carried out the study on 37 patients over the course of 24 weeks

Brussels elgian biotech firm Ablynx said a clinical study of its rheumatoid arthritis drug ALX-0061 showed promising results and it was now considering how to further develop the drug, including a partner-

B

34

EXPRESS PHARMA

www.expresspharmaonline.com

ship deal with a bigger company.

“We are now investigating the various possibilities through which we can progress the development of ALX-0061, including discussions with potential partners and other paths which will allow us to maximise the

value of this asset,” Edwin Moses, Chief Executive Officer, Ablynx said. Ablynx had carried out the study on 37 patients over the course of 24 weeks and said the drug was well-tolerated and showed positive results.

Reuters March 1-15, 2013

R|E|S|E|A|R|C|H

Oncolytics lung cancer drug shrinks tumours in 95 per cent patients The drug, Reolysin, was used intravenously in combination with chemotherapy drugs carboplatin and paclitaxel ncolytics Biotech said a mid-stage trial of its experimental lung cancer drug showed that 95 per cent of the patients experienced a reduction in the size of their tumours. The drug, Reolysin, was used intravenously in combination with chemotherapy drugs carboplatin and paclitaxel. It was tested on patients suffering from metastatic, or recurrent squamous cell carcinoma of the lung.

Squamous cell carcinomas

O

account for about a fourth of all lung cancers, the company said. However, Oppenheimer & Co analyst Boris Peaker said in a note the single-arm study was inconclusive and the spike in the company's stock

price associated with this news was not warranted.

“Since the chemotherapy itself is highly active, it is difficult to estimate the impact that Reolysin is making,” said Peaker, who kept his 'per-

form' rating on the stock. The company said the results further suggest that Reolysin may have potential use in presurgical settings. “Based on these findings we intend to continue to look at Reolysin as a treatment for cancers of the lung and cancers that metastasize to the lung,” Brad

Thompson, Chief Executive said.

Calgary-based Oncolytics said in September the first part of a mid-stage trial of its lung cancer drug met the main goal of showing patient response.

Reuters

Eli Lilly stops development of rheumatoid arthritis drug Data from a late-stage trial showed the drug was unlikely to prove effective li Lilly will stop developing its experimental rheumatoid arthritis drug tabalumab, nearly two months after data from a late-stage trial showed the drug was unlikely to prove effective. The trial, one of the three late-stage trials planned for the drug, was testing tabalumab in patients with moderate-to-severe rheumatoid arthritis who had an inadequate response to initial treatment. Lilly conducted another analysis before stopping all ongoing mid- and late-stage trials of the drug. The decision is expected to result in a firstquarter charge of about $50 million. However, the company's financial forecast for 2013 remained unchanged.

Rheumatoid arthritis is an autoimmune disorder that causes inflammation and damage to the joints and surrounding tissues. An estimated 1.3 million people in the US have rheumatoid arthritis, according to advocacy group Arthritis Foundation. Tabalumab will continue to be tested in latestage development as a treatment for the autoimmune disorder called systemic lupus erythematosus, and in midstage development for multiple myeloma.

Reuters

E

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

35

W H AT ’ S INSIDE

Metrohm and FOSS enter strategic alliance PG 37 Everything under control in laboratory and production PG 38 Influence of cold forming and product geometry on the size of cold form blister PG 40

Pharma Life PG 62 36

EXPRESS PHARMA

PHARMA ALLY ‘India is a focus market of high strategic importance for us’ With the inauguration of a new facility in Jambusar (Gujarat), which also happens to be India's first completely automated pharmaceutical packaging plant, SCHOTT KAISHA has shown its big plans for the Indian market. Kairus Dadachanji, Managing Director, SCHOTT KAISHA, reveals more to Sachin Jagdale SCHOTT KAISHA has recently inaugurated its Jambusar facility in India.

In what way will this new facility cater to company’s needs in India and overseas?

SCHOTT KAISHA’s stateof-the-art facility enables us to help Indian pharmaceutical companies to meet increasingly sophisticated market demands in India in terms of quality, innovation and differentiation.

The new facility in Jambusar is India’s first completely automated pharma packaging plant. It uses highend robotic feeding technology for tube-loading, fully inline automatic process and high-precision camera inspection systems. This guarantees an extremely efficient and reliable production process of consistent quality, underlining our commitment to the international good manufacturing practice (GMP) standards.

India’s pharma market enjoys sustained, strong growth which is directly proportionate to the demand for locally manufactured primary packaging. By steadily advancing with the Indian pharma industry and therefore understanding the specific needs and challenges of the Indian market, we have already emerged as one of the leading pharma packaging companies in India.

The new facility enables SCHOTT KAISHA to help customers achieve their own growth and quality objectives in India. This Greenfield investment increases the SCHOTT KAISHA production capacity by 50 per cent to around 2.4 billion ampoules and vials per year.

India is already among the top 20 pharma exporting countries and the exports have grown significantly.

Drugs manufactured in India are delivered to more than

200 countries including the US, the UK and countries of the EU. The industry is boosted by global exports from India’s state-of-the-art pharma manufacturers.

SCHOTT KAISHA is keen to support the nation’s success with state-of-the-art packaging solutions.

All this sets new standards in India and enhances SCHOTT KAISHA’s competitive advantage substantially.

How much has been invested to construct this facility?

Is there a scope for further investment in the same plant? If yes, will the investment be made in the same product category?

India is a focus market of high strategic importance for us and we are growing together with our partners and customers. Therefore, SCHOTT KAISHA invested more than `136 crores in this facility.

The plant in Jambusar has 20 production lines for ampoules and 16 for vials, with scope for further expansion. The facility is housed in an area of 20 acres with ample room to construct further production modules in parallel with the increasing demand of customers. The growing importance of this market is the reason why we are already planning to expand the plant in the near future. We are currently working on the exact timing of the next investment phases and scope of expansion. For other products too, we are closely monitoring market conditions. If there is appropriate requirement we will certainly invest.

How much revenue of SCHOTT KAISHA comes from India operations?

We produce in India for the Indian market. As part of our corporate policy, the SCHOTT Group does not diswww.expresspharmaonline.com

INTERVIEW

close revenues of its business units. But to give you an impression – SCHOTT KAISHA turnover increased almost threefold since 2008.

This represents an average growth of 25 per cent per annum. SCHOTT KAISHA is confident of exceeding overall market growth also in the future.

Is India the only country where SCHOTT has chosen the business partnership route? If not, kindly give details of your other alliances.

I can answer this question on behalf of our joint venture partner SCHOTT: Regarding their pharma systems business, the international SCHOTT Group has also established a joint venture with Xinkang in China that has recently started operations. Beyond this, SCHOTT Pharmaceutical Systems operates almost 800 production lines and 17 plants for pharma packaging as well as five tubing plants in 14 countries worldwide.

They are producing more than nine billion syringes, vials, ampoules, cartridges and special articles of tubing glass or polymer.

What are the current challenges for Indian and global packaging manufacturers?

The biggest challenge we face is to keep up with the extraordinary demand of the market. As India’s pharma market grows in size, the demand for better packaging is growing. This is also a main reason why we have set up an extra plant with considerable expansion plans to grow in parallel to the demand.

Due to the sheer size of the country logistic challenges cannot be overlooked.

That is why the plant in Jambusar is situated right next to SCHOTT’s tubing facility in order to ensure timely and efficient supply of the most important base material- world market leading SCHOTT FIOLAX tubes.

In addition to this, we have an excellent Indian team and our back-up possibilities offered by our production sites situated all over the world, provide flexibility, reliability and security to our partners in India.

Besides India, which other countries would SCHOTT KAISHA like to set up its plants?

SCHOTT KAISHA is an Indian joint venture and will therefore cater primarily to the Indian market. We are part of the international network of SCHOTT Pharmaceutical Systems. As one of the world’s leading suppliers of parenteral packaging for the pharma industry SCHOTT has almost 800 production lines in 14 countries worldwide producing nine billion syringes, vials, ampoules, cartridges and special articles of glass tubing or polymer. SCHOTT is steadily investing and advancing its global footprint.

Sachin.jagdale@expressindia.com March 1-15, 2013

P|H|A|R|M|A| A|L|L|Y

VENDOR NEWS Metrohm and FOSS enter strategic alliance Metrohm will become the sole global distributor of FOSS NIR instruments etrohm and FOSS have entered into a strategic alliance strengthening the two companies’ leading positions in their respective key markets. In this strategic alliance, Metrohm will become the sole global distributor of FOSS NIR instruments for the chemical, petrochemical, pharmaceutical, and environmental sectors.

“Metrohm will extend its product offering beyond the company’s traditional focus on solutions for wet-chemistry analytical techniques thereby benefiting our customers with new possibilities both in laboratory and process analysis”, said Dr Christoph Fässler, Chief Executive Officer, Metrohm.

FOSS will continue its strong R&D programme within NIR technology and manufacturing for both companies.

“The strategic alliance allows FOSS to focus its NIR business on the Food & Agricultural industries that we have served for more than 50 years, while continuing our leading position within NIR technology – and making this technology available to a broader customer base,” said Torben Ladegaard, Chief Executive Officer, FOSS. Under the deal, FOSS NIRSystems, based in Laurel, Maryland, US, will become a division of Metrohm USA to be named Metrohm NIRSystems.

“With Metrohm’s strong worldwide presence, commitment to the pharma and chemical industries, and with this investment in NIR the alliance allows us to further grow our business within these sectors and provide our customers with a steady stream of new innovative NIR products and the highest level of support,” said Dr Philip Irving, President, FOSS NIRSystems. The global NIR instrument business for these sectors will continue to be run by the Metrohm NIRSystems division of Metrohm US. Family-owned FOSS is the world’s leading supplier of dedicated analytical solu-

M

March 1-15, 2013

tions that ensure optimal quality and production of

food and agricultural products. FOSS solutions analyse and control products during production - helping to optimise both quality and profit.

FOSS has manufacturing

www.expresspharmaonline.com

and research and development facilities in Denmark, Sweden and China with headquarters in Hilleroed, Denmark. Solutions are sold and supported through 27

FOSS sales and service companies in Europe, Americas and Asia/Pacific, as well as through an extensive global network of distributors.

EP News Bureau- Mumbai

EXPRESS PHARMA

37

P|H|A|R|M|A| A|L|L|Y

VALUE AD Everything under control in laboratory and production Angelika Scheiflinger-Latal, Market Development Pharma, Anton Paar, gives an insight about the company’s comprehensive product portfolio for R&D, production and quality control in pharmaceutical sector harmaceutical companies work throughout their supply chain in a field which is dominated by regulations and demands for high quality. Defined workflows, trained personnel and reliable instruments and plants are important cornerstones of pharma production. Anton Paar provides a comprehensive product portfolio for R&D, production and quality control.

One of the main fields of use for density measurement is quality control, as it quickly delivers an unambiguous physical parameter as the result. Density gives insight into the condition of pharma raw materials, i.e. media which are currently in the production process, as well as into the finished medicine. This makes it possible to intervene quickly and decide whether the production and the final product are within the defined specifications for continuing the process and approving the product. An added plus is the combination of density and sound velocity measurement, which delivers highly precise and reproducible results for complex three-component solutions.

This makes the use of density meters unique for the characterisation and method development of complex liq-

P

uids in R&D in order to determine common pharmaspecific quality parameters.

Density measurement is based on the oscillating Utube principle and corresponds to the requirements of pharmacopoeia such as USP, Ph.EU, JP, MX. This enables direct comparison of results from laboratory and online measurement.

For all relevant wavelengths The optical rotation is an essential measurement parameter in the pharma industry. It is used to determine the quality and purity of raw materials and for

MCP polarimeters are suitable for incoming checks to quickly identify raw materials and for quality control because identical molecules with other optical properties may display no or toxic attributes. Manufacturers in

ONE OF THE MAIN FIELDS OF USE FOR DENSITY MEASUREMENT IS QUALITY CONTROL, AS IT QUICKLY DELIVERS AN UNAMBIGUOUS PHYSICAL PARAMETER AS THE RESULT. DENSITY GIVES INSIGHT INTO THE CONDITION OF PHARMA RAW MATERIALS

identifying pharma substances. Besides the purity, the first identification of the optical rotation of the used active ingredient is essential

the pharma industry have to guarantee and ensure a consistent quality of the medicine so that it poses no danger for the end customer or patient. MCP polarimeters are the ideal instruments for quick incoming checks on raw materials, for reliably identifiying correct substances during production and in the final product as part of quality control. The Propol online polarimeter enables real-time monitoring of the correct production and formation of an active ingredient in the correct chirality.

Refractive index: quickly determined DMA Generation M density meters are ideal for use in production, predominantly in quality control

38

EXPRESS PHARMA

www.expresspharmaonline.com

The refractive index is a quickly accessible and easy to determine parameter

which enables the measurement of different samples.

The measuring principle enables measurement of liquids, pastes and solids, as well as turbid, coloured and opaque samples. As the refractive index correlates with the concentration of a dissolved substance, the refractive index measurement can be used to determine the concentration. For quality control laboratories in particular, it is important to have reproducible results available simply and quickly for the approval of batches or correction of the ongoing production. Abbemat refractometers require no sample preparation and only low sample volumes, and are therefore optimal, time-saving refractometers.

Trace analysis: a clear solution The various pharmacopoeia dictate that pharma compounds must be investigated to ensure that any heavy metals contained are within the prescribed limits.

They also specify the method of sample preparation to be used. The Multiwave 3000 digestion instrument based on microwave technology allows quick and complete acid digestion of different pharma raw materials and end products. Using this digestion instrument enables high sample March 1-15, 2013

P|H|A|R|M|A| A|L|L|Y

Abbemat refractometers quickly and easily determine the refractive index of batches and allow correction of ongoing production throughput at homogeneous temperature distribution.

The sensors and automatic reports make reactions traceably documented both for the development and validation of methods and for routine operation. To guarantee a sufficient concentration of the substances for analysis and to meet different pharma needs for digestion requires special digestion techniques. The wide range of offered digestion instruments exactly meets these requirements.

of the suitable reaction parameters from the small scale to the kilolab scale is now possible with the monomode reactor without adjusting the methods and technology.

Microwaveassisted synthesis with the monomode reactor is particularly suitable for the manufacture of expensive and difficult to access pharma agents in small amounts.

dependent on the different substances which are dissolved in the formulation. If flow properties are outside the limits during production this can result in process steps, such as homogenizing, pumping and filling, running below the required effectiveness or cause changes to active agents.

This can result in enormous costs. The size of dissolved particles in pharma compounds, such as infusion solutions, emulsions or creams, is critical in order to ensure that they are infused and transported in the blood flow without pain to the patient or that creams overcome the skin barrier. The MCR rheometers are ideal for defining the flow properties, process parameters and stabilities of the products.

SAXS method gives insight into the aggregation and denaturation behaviour of proteins and also into particle size and particle size distribution in formulations.

Structural parameters have a considerable influence on the solubility, stability and shelf life of medicines. A fully automatic small-angle X-ray measurement with SAXSess mc2 makes this complex measuring method easy to use.

Analysis of solid surfaces In the field of medicine, pharma substances should not be affected by the used materials. During dialysis, for example, no substances should diffuse out of the tubes and no substances intended for the patient should be adsorbed by the

Investigating the flow behaviour

The measurement of liquids to investigate their viscous and viscoelastic behavSynthesis: from mg to kg Conventional organic iour is a relevant quality synthesis, which is the basis parameter in the pharma for the development and industry. It is important to often for the production of determine the flow properpharma components and ties of formulations, from substances, is a complex, infusion solutions to oint- Small-angle X-ray scattering systems such as the SAXSess mc2 from time-consuming and ments, under controlled Anton Paar give insight into the atomic and molecular structure of resource-intensive proce- conditions and to optimise active agents and formulations dure. Using microwave syn- the formulations to ensure MCR rheometers tubes. The same is required thesis reduces costs for that products in production The chemicals and synthesis and the finished products answer all rheological ques- of the containers for pharma time. The selected synthesis have the required proper- tions in the pharma sector. products, e.g. infusion bags, steps in the small scale can ties. Flow properties are glass vials, disposable also be optimised during the dependent on ambient con- X-ray: From solid to liquid syringes, etc. The surface of development process in the ditions such as temperature X-ray structure analysis all these materials must not multimode reactor. Transfer and outside forces and also gives insight into the internal interact with the contained atomic and molecular struc- media in order to prevent ture of pharma active agents the impact of the medicine and formulations and pro- being changed or influvides information on the sta- enced. In the different steps bility of these under different of pharma production it is conditions, e.g. different also important to ensure temperatures and levels of that required substances do humidity. The exact determi- not adsorb on filters, e.g. nation of the crystalline when filtering production structure and the detection solutions. The SurPASS elecof any crystalline impurities trokinetic analyzer for surin active agents and final face characterisation determedicines are both essential mines zeta potential and for guaranteeing the medi- allows investigations into cines' properties and ensur- the interaction between the ing flawless production used material and the differprocesses. Using the small- ent components, such as angle X-ray scattering (SAXS) pharma active agents, prosystem, SAXSess mc2, sam- teins and different excipiples can be measured in both ents. The used material can the liquid and solid state and then be optimised for the Using the Monowave 300 microwave reactor, synthesis steps can be in the final product. The individual requirements. optimised in small scale during the development process March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

39

P|H|A|R|M|A| A|L|L|Y

VALUE AD Influence of cold forming and product geometry on the size of cold form blister Dr Erwin Pasbrig, Director, R&D, Ansapack, in a white paper talks about cold form geometry in pharmaceutical industry he pharmaceutical industry is constantly developing new substances and drug delivery systems (DDS) which require ‘absolute’ protection in reference to humidity and oxygen.

For these applications the barrier of thermoformed blisters made of high barrier plastics such as ACLAR- and COClaminates is no longer sufficient. Self-evidently the blisters could be additionally packed in pouches.

Nevertheless this would increase costs for production as well as for the packaging material used for the pharma company.

Laminate for blisters with aluminium as barrier layer (CFF; Panblok; alu-alu-blister) provide barrier from top and bottom. Products packed in CFF have the optimum protection against outer influences.

The forming procedure is carried out with plugs and without thermo-forming techniques (no heating of laminate prior to forming) thus the blisters are 2.5 to three times larger than thermo-formed plastic blisters. Some machine manufacturers have accumulated a great deal of experience thus they manufacture formats for tools themselves and use existing tools for standard package dimensions (e.g. capsules), others do not have this experience and the result of cold formed result could be relatively an under performer.

Pharma companies also tend to have tool manufacturers 'copy' tools for existing products. This is the case in particular in Asia, and South America but is also no exception in Europe. The problem might arise in these cases is that the plug geometry is not identical with the original. If an existing cavity is measured the following data are still unknown: ● Exact dimension (steps and angles) ● Plug material, ● Forming depth, ● Space between plug - die.

In 99 per cent of these

T

40

EXPRESS PHARMA

cases a new tool has to be calculated if pinholes and tears form with this tool. The cavity requires larger dimensions in order to achieve faultless forming results. This usually calls for new sealing tools, perforations, embossing station, larger folding cartons and eventually it translates to a higher cost. Due to the aforementioned reasons it is highly recommend to make use of the original machine producer or experienced tool maker for the parts as required during cold forming.

Whether or not the size of a cavity is correct can be roughly checked by dividing the width or diameter of the

cavity by its height. The geometry of the filling good has also to be taken into account (Table 1).

For rotary sealing the cavities have to fit exactly into the format of the transporting roller so that faultless transport of the formed laminate is safeguarded.

In order to safeguard faultless forming of the material these cavities are – in relation to the standards used for platen sealing – mostly larger. As this sealing technology for cold forming is still relatively new – with the exception of IMA – these statements are not yet statistically assured.

Application of different plug materials against the PVC sealing layer results in distinct forming ratios:

Caplet Teflon = 2.8 – 3.2 S-green = 2.9 – 3.4 POM = 3.4 – 3.5 The forming ratio changes due to the distinct coefficients of friction against the sealing layer. Increased friction results in insufficient material flow during forming. The material is mainly stretched in the first third – related to the radius of the die. In this area the laminate is extremely downgauged, and thus pinholes form or the material might even tear (Drawing 1). The colour shades from yellow to red in the critical area of forming depicts the down-gauging of the material. At the same time the laminate is increasingly mono-axially stretched, the curve in the diagram moves increasingly to the y-axis.

Table 1: Relation Height to width/diameter (plug = Teflon)

Drawing 1: Influence of plug material on forming properties

Table 2: Ratio of coefficient of friction of sealing layer – forming plug Plug material

PVC

HDPE

Teflon

1

1

UHMW-PE (S-green)

1.4

2.7

POM

2.2

1.3

Steel

3

1.3

www.expresspharmaonline.com

March 1-15, 2013

P|H|A|R|M|A| A|L|L|Y

during forming process; pinholes or tears might form.

A frequent question of users of CFF is always: how long the plug can be used before wearing out and how long before they have to be changed? There is no answer in general. If tooling is handled correctly (cleaned fre-

Nevertheless this does not mean that other plug materials cannot be used. Tough more laminate is required for the forming process, the cavity – used for the same filling good – becomes larger and thus the requirement of packaging material increases. Three calculations from practical appli-

Results are pinholes and possible cracks.

Check of CFF blisters Processing of cold forming might result in formation of pinholes or material tears.

The 100 per cent safe in-line check with a pinhole detector (info@hpf-elektronik.de;

Atrovastatin (L x W x H; R = 12.3 x 6.5 x 4.9; 5, head space 0.3 mm) Cavity with Teflon 21.0 x 15.2 mm, Blister = 97 x 53 mm ➨100,000 Cavity with S-green 23.2 x 17.4 mm, Blister = 108 x 57.5 mm ➨100,000 Capsule Size 3 (Ø 5.8; Length 16.0 mm, head space 0.3 mm) Cavity with Teflon 27.6 x 17.4 mm, Blister = 108 x 66 mm ➨100,000 Cavity with S-green 30.0 x 19.8 mm, Blister = 120.5 x 71 mm ➨100,000 Capsule Size 0 (Ø 7.0; Length 21.5 mm, head space 0.4 mm) Cavity with Teflon 36.8 x 23.0 mm, Blister = 136 x 84.5 mm ➨100,000 Cavity with Steel 48.8 x 35.0 mm, Blister = 196 x 108.5 mm ➨100,000

quently and not damaged) six months with 24 hours production is possible. This is an example from praxis: blister for Pantoprazol with HDPE as sealing layer and Teflon as plug material.

Production environment has a big influence on the result of coldforming. As it was pointed out before, CoF between plug and sealing layer is mainly factor for the correct forming (no defects).

If temperature is increasing in production the CoF will increase as well. Normal conditions are 22 – 25 degree C and 50 – 60 per cent r.h. If oPA is absorbing an excessive amount of humidity it becomes 'soft' and does not protect forming of aluminium.

cations are provided below: The coefficient of friction might change if distinct sealing layers are applied (Table 2).

The decision about the respective material is with the machine manufacturer and respectively the customer.

This depends mainly on the capability of tool manufacturer to work with Teflon and handling of tool within the production area. If soft plug material is used the plug geometry might be altered due to inappropriate handling such as putting the plug on hard surfaces, scratches caused by finger nails or tools). Application of these faulty plugs has an impact on the stretch of CFF laminate Product (mm) Ø

Olanzapine

Cavity (mm)

w w w. h p f - e l e k t ro n i k . d e ) detects these types of faults, and the faulty forming cycles are eliminated. Nevertheless this means increased costs and decreased productivity. ● The causes for pinholes/tears: ● Laminate ● Tool geometry ● Centring of plugs ● Distance of plug - matrix ● Damaged plug ● Not correct processing ● Environment of production ● Environment of storage

Influence of the filling good on the dimension of the cavity Size and geometry of the filling good has a major influence on the dimension of the

Blister (mm)

Ø

Length

Width

Surface (cm²)

5.0

16.1

101.5

43.0

43.6

92

5.0

9.0

16.9

105.5

45.0

47.5

100

17.0

18.3

112.5

47.5

53.4

112

Width

18.25

Blisters = 1,149 m² Blisters = 2,127 m²

Radius

Product (mm)

Mups

Blisters = 713 m² Blisters = 856 m²

Height

9.0

Length

Blisters = 514 m² Blisters = 621 m²

8.25

Cavity (mm)

Height

5.5

Ratio

Blister (mm)

Radius

Length

Width

Length

Width

Surface (cm²)

Ratio

6.0

27.5

17.5

108.5

66.0

71.6

93

12.0

28.4

18.4

113.0

68.0

76.8

100

18.0

29.3

19.3

117.5

69.5

81.7

106

design: edge to cavity: 4 mm, space cavity – cavity: 3 mm last tablet to end of blister (embossing of lot number, expiration date): 7 mm

Table 3: Influence of the height of the product on the size of the cavity Product

Cavity

Blister

Ø

Height

Ø

Length

Width

Surface (cm²)

Ratio

8.0

6.56

23.6

139.0

58.0

80.6

154

10.0

4.20

18.0

111.0

47.0

52.2

100

12.0

2.92

15.4

98.0

42.0

41.2

79

March 1-15, 2013

www.expresspharmaonline.com

cavity, and thus on the requirement of packaging material. The decisive factor is the ratio of height to width.

The smallest cavities are those of capsules. It would be ideal if also tablets would be produced in this shape. Whether or not a tablet or a capsule is used as DDS depends mainly on the mode of action of the active substances and the processability of the drug.

Nevertheless, the geometry of the tablets cannot exclusively be adjusted to the smallest cavity possible. Other features such as type of application, release of active substances within certain parts of the body, compressibility of the substances, and further conditioning factors have an influence on the form of the tablet.1 Ideal processing is freezedrying of the product in the cavity. Using this process by Catalant (formerly RP Scherer) the size of the cavity is identical with the size of the thermoformed blister, if a special laminate is used.

Nevertheless also normal tablets could be packed in smaller cavities after slight changes of their geometry.

Decreasing of the radius of round bi-convex tablets or oblong bi-convex tablets (Caplet) results in smaller cavities. We chose the round bi-convex tablet 'Olanzapine', and Caplet 'Mups' as examples.

Another possibility to decrease material requirement is achieved by decreasing the height of the product while maintaining the volume. This is depicted on the example of a round, flat tablet (10 x 4.2 mm, volume = 329.7 mm³) (Table 3).

Apart from these mentioned possibilities for processing of ideal cavities there is also the opportunity to apply special Panblok material. The limit of formability with these laminates is > 35 per cent, the standard can be stretched 30 per cent 3 D. By application of plastics as sealing layer with increased barrier properties against water vapour and oxygen, or significant decrease of foil gauge the diffusion through the edges of cut of the blister (land area) is achieved, and thus the shelf life of the active substances also increased.

1.

W.A.Ritschel; A.Bauer-Brandl, „Die Tablette“, 2nd edition, published by: Editio Cantor Verlag Aulendorf, 2002 EXPRESS PHARMA

41

P|H|A|R|M|A| A|L|L|Y

PRODUCTS Thermo Fisher Scientific introduces new innovatively designed pipetting system hermo Fisher Scientific, the world leader in serving science, has introduced the new Thermo Scientific F1-ClipTip pipetting system, enabling users to deliver consistent, reproducible pipetting with higher-quality results. Its revolutionary ClipTip interlocking technology locks tips securely into place to deliver an airtight seal on every channel.

Raymond Mercier, liquid transfer product Director of Thermo Fisher, “Researchers are constantly challenged with pipette tips that leak air, loosen or fall off in the middle of their protocols, ruining or contaminating the assay.

Our new F1-ClipTip pipetting system’s breakthrough interlocking design securely locks tips in place, which increases reproducibility, reduces force required to attach the tips and ensures the best possible

T

accuracy and precision.”

Available for both single and multichannel pipettes, the Thermo Scientific F1ClipTip pipetting system is simple but powerful. With minimal force, each tip is clipped securely on the F1ClipTip pipette using a patented three-interlocking clip design. The pipette and tip form a complete seal to secure the sample volume in each tip for enhanced accuracy and precision.

Additional features include: ● Ergonomic design: Low tip attachment, ejection and plunger forces for safe and comfortableuse, reducing the risk of repetitive strain injuries (RSI) ● Exceptionally lightweight: Reduced fatigue during extended periods of pipetting ● Adjustable 120° finger

●

●

●

rest: For both right- and left-handed operator comfort – allows the hand to relax during pipetting cycles Patented super blow-out: 150 per cent increase in air boost to ensure efficient delivery of microvolumes and prevent capillary action for low volume pipetting Patented soft-touch tip ejection: Innovative gearing mechanism produces more downward force with less effort, releasing tips with a gentle push Volume lock adjustment: Secure volume setting prevents undesirable volume drift during operation.

Contact details: Meenal Shinde Thermo Fisher Scientific India Telephone: +91 22 6716 2200

Toll Free No: 1800 22 8374 Email : reply.lpg.india@thermofisher.com www.thermofisher.com or www.thermo.com

Barcode verifiers by Sandilyam Automation Systems andilyam Automation Systems, which specialises in barcode verification and barcode standards, with AXICON, who are leaders in barcode verification globally, have a range of systems and globally acclaimed barcode verifiers, which are most comprehensive and flexible verification solutions in the market today.

The Axicon 12000 - 2D

S

42

EXPRESS PHARMA

verifier is designed for verifying 2D bar codes such as Data Matrix, GS1 Databar codes, QR codes, PDF and micro PDF codes, with ease and really operates as a plug and play system. All barcodes are verified as per the latest ISO, GS1 and pharmaceutical standards. The Axicon 12000 also provides a solution for a wide range of application standards including Turkish Ministry of Health & CIP (France).

Designed for all 2D barcodes where an aperture size of 3mil or more is required (up to the scan area available). This system is widely used by leading pharmaceutical product manufacturers, label printers, printers and packagers.

The system consists of, high accuracy camera-based optics, certifications, user calibration card, with necessary interface cables all built into a carry case. The 12000 is in full compliance to ISO 15415 Print quality specifications, and the system itself is as per ISO 15426-2 verifier conformance standards. The verifier also meets the stringent 21 CFR part II requirements.

An essential accessory www.expresspharmaonline.com

especially for those customers printing DataMatrix barcodes on-line – is a precision set created to help you maximise the performance of your on-line printing & scanning systems.

Ever wondered why the results from your on-line scanning system differ from those on your ISO grade verifier?

Well, the answer is that the results from the scanner will vary according to the distance from the barcode, angle of scan, ambient light levels, the wavelength of light. The 'Axicon Technical Reference cards' help eliminate this issue by providing you with the tools and information you need to optimise the position of your on-line scanner.

To tackle effectively the potential areas of mistakes in printing 2D Datamatrix barcodes, the 12000 verifier is an invaluable tool. Important amongst this is the structure of the symbol identified by a perimeter where scanners begin their attempt to read the encoded data. Some of the critical elements of ISO/IEC 15415 in assessing the quality of the printed Datamatrix code which the 12000 will provide

analysis on, include: ● Axial non-uniformity ● Fixed pattern damage ● Grid non-uniformity ● Modulation ● Symbol contrast ● Decode ● Unused error correction ● Reflectance margin ● Quiet zones ● Transition ratios

It is important not to mistake scanning with verification and this is a very critical link within control and scope of the pharmaceutical manufacturer. No scanning system will be able to reliably assess and measure barcode quality as defined by ISO/IEC with repeatability and consistency, to be able to assure scannability in any other scanning environment further down the supply chain.

Contact details: Sandilyam Automation Systems # 203 Money Chambers, 6 KH Road, Bangalore 560027 Phone: +91 80 6598 8333, 2211 0520 Email: gen@sandilyam.com website: www.barcodeglobal.com March 1-15, 2013

Express Pharma Business Avenues World Class Bottle Packaging line solution from Countec, Korea New!!! 200 Bottles/minute Tablet-Capsule Bottle Packaging Line

Twice the speed, half the space!!!

New!!!

New!!!

Verification Counting Machine DMC CQ2

New!!!

Bench Top Counter DMC 4

New!!!

Electronic Tablet Counting Model DMC120T/DMC200

High Speed Rotary Screw Capper with Servo Motor Control CT-RC-120/200

Our range of packaging systems include 60BPM, 120BPM & 200BPM container packing line · ·

Mono block unscrambler with air jet cleaner Sachet desiccant inserter

· ·

Case packer Metal detector

·

Canister desiccant inserter

·

Induction sealer

· ·

Electronic tablet counter Tare/Gross check weighing system

· ·

Servo controlled Retorquer Self adhesive labeler

·

Automatic tablet loader

·

Leaflet outserter

· ·

Cap loading system machine Servo controlled Rotary Capping machine

· ·

In feed out feed turn tables Complete line up & Integrations

·

Cotton wool inserting machine

·

Validation support

Manufactured by Countec Ltd, South Korea

Sole Representative in India

Leading world technology today. Driving innovation forward tomorrow.

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

43

Express Pharma Business Avenues

Fast relief from production headaches

DEHUMIDIFIERS The simplest, most effective method of humidity control

FLi Helps meet GMP requirements FLB 10,000 + cmh

2,000 - 10,000 cmh

FFB 170 to 2,000 cmh

The first choice of Pharma Industry ... worldwide For over four decades, Bry-Air Dehumidifiers are being used by the Pharma industry during production, processing, storage and packaging to solve moisture / humidity related problems like lumping, disintegration of tablets, etc. Bacteria-free dehumidified air helps improve quality and extend shelf life of the products.

Backed by

Call us today for free consultancy

ISO 9001:2008 & 14001:2004 CERTIFIED

RB/BA/1210HHCA1

Service

You will be surprised how easy it is to improve your quality and productivity. www.bryair.com

Phone: +91 11 23906777 • E-Mail: bryairmarketing@pahwa.com USA | Brazil | Italy | Turkey | South Africa | UAE | India | China | Malaysia | Indonesia | Philippines | Japan | Australia

44

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

45

Express Pharma Business Avenues We care for your family . . .

Anti-Inflammatory Enzymes Serratiopeptidase Peptizyme (enteric coated serratiopeptidase granules) Trypsin Chymotrypsin mix ( 6:1)

Probiotics Saccharomyces boulardii Lactic acid basillus sporogenous

Circulatory Health Nattokinase

Bio Catalysts Immobilized Cal B

Digestive Aids Alpha amylase / fungal diastase / fungal amylase Alpha galactosidase Bacterial alpha amylase Bromelain Hemicellulase Lactase Lipase Ox bile

Papain Pepsin Pancreatin Protease ( acid / alkali)

Advanced Enzyme Technologies Limited Sun Magnetica, 'A' wing, 5th Floor, Accolade Galaxy, LIC Service Road, Louiswadi, Thane(W) - 400604, India Tel: +91 22 41703200, Fax: +91 22 25835159 • E-mail : info@enzymeindia.com • Website: www.enzymeindia.com

46

EXPRESS PHARMA

www.expresspharmaonline.com

Non-GMO ISO CERTIFICATION

GOTS CERTIFICATION

Products

WHO cGMP

FDA

March 1-15, 2013

Express Pharma Business Avenues

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

47

Express Pharma Business Avenues

“ The 1st Indian Silicone Rubber Product Mfg. co, certified with Clean Room of class 10000” SILICONE RUBBER PRODUCT G Silicone Transparent Tubing's (USP / FDA Grade) G Silicone Transparent Braided Hose (USP / FDA Grade) G FBD Inflatable Gaskets in Silicone Transparent G Rubber and also in Food Grade Neoprene Rubber

Silicone Transparent Tubing & Braided Hose Conforms to USP Class VI Requirement & FDA 21 CFR 177.2600 (AVAILABLE IN PLATINUM & PEROXIDE CURED)

Silicone & Viton Rubber O Rings

G Platinum Cured Silicone Transparent Tubes G Platinum Cured Silicone Transparent Braided Hose G Platinum Cured Silicone T/c Gaskets G Silicone Extruded Door Gaskets (Autoclavable)

FBD Inflatable Gasket Conformd to FDA 21 CFR 177.2600

Silicone Extruded Door Gasket

G Silicone Stripss, Cords &sponge Gaskets ISO 14644-1 Certified Clean Room

G Rubber Expansion Joint/Bellows G Viton O-Rings, Cords & Strips G O-Rings (Viton & Silicone)

Quality Management System

Environmental Management System Occupational Health Safety Assessment System

G Tri Clover Gasket

Ami Polymer Pvt. Ltd. (The Sealing Expert in Silicone Rubber)An ISO : 2008 Certified Co.)

G Silicone & Viton Sheets

303, Mahesh Industrial Estate,Opp.Silver Park, Mira Bhayandar Rd.,Mira Road (E), Dist. Thane, Mumbai-401 104 Tel.: 91-22-28555107/ 28555631/ 28555914 Fax : 91-22-28555378 Email :amipolymer@vsnl.com Url : www. amipolymer.com

BRANCHES

48

HYDERABAD

BADDI (H.P)

BANGALURU

ROORKEE

MAHARASHTRA

GOA

INDORE

09246502943/42 hybd@amipolymer.com

09218595103 / 09218595011 Baddi@amipolymer.com

09916072800/ 08691013931 bngl@amipolymer.com

09219691095/ 09219521095 roorkee@amipolymer.com

09223290933/ 09223290933 amipolymer@vsnl.com

09223290935 goa@amipolymer.com

07869267791/ 09816595011

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

49

Express Pharma Business Avenues Successful Installation in Beverage Ind. upto 25Kl/hr.

More than 50 Filter Presses are in Operation

Product Range : Horizontal Plate Filter Press Plate And Frame Filter Press Bag Filter Cartridge Filter Single Plate Filter Holder Basket Filter Rotary Spray Ball Recess Plate Filter Press

Parksan Filters Pvt. Ltd. 103, Laxmi Industrial Estate, Navghar, Vasai Road (East), Dist: Thane - 401 210, India T : +91 250 239 1904 Mob : +91 98338 83114 E : sales@parksanfilters.com Web : www.parksanfilters.com

50

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

51

Express Pharma Business Avenues

52

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues

54

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

55

Express Pharma Business Avenues

56

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

57

Express Pharma Business Avenues

58

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues

pure science – no fiction

R ap G e n i d an d t le D r y in g

Fluid Bed Dryer TG 200 ■ Strong blower allows for optimized air flow and increased drying capacity ■ Maximum drying temperature up to 150 °C ■ Digital controls for temperature, time and air flow ■ Interval mode for improved mixture of fluidized bed www.retsch.com/tg200 RETSCH INDIA PVT LTD, 1-2-45/1, 2nd Floor, Street No: 2, Kakatiya Nagar Colony, Habsiguda, 500 007 Hyderabad, India Phone: +91 40 2717 2431, Fax: +91 40 2715 4686 E-mail: info@retsch.co.in, Web: www.retsch.co.in

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

59

Express Pharma Business Avenues Advertise in

Business Avenues Please Contact: ■ Mumbai: Rajesh Bhatkal 09821313017 ■ Delhi: Ambuj Kumar 09999070900 ■ Chennai: Vijay Kulkarni 09940047667 ■ Bangalore: Khaja Ali 09741100008 ■ Hyderabad: A K Shukla 09849297724 ■ Kolkata: Ajanta / Prasenjit Basu 09831182580 / 09830130965 ■ Ahmedabad: Rajesh Bhatkal 09821313017

60

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

Express Pharma Business Avenues WANTED MANUFACTURERS WITH SPARE CAPACITY IN INJECTABLE FORMULATION MINIMUM 3 MILLION AMPOULES PER MONTH.

We are a part of the internationally renowned Multinational Pharmaceutical & Chemical Group that operates Worldwide.

We require reliable manufacturers having additional capacity to manufacture our branded formulations on Loan Licence basis for1. Injectable Formulation Small Volume Parenteral 2. Spare capacity required for 3 million ampoules per month 3. Criteria for selection : ● The facility should have sterilization Tunnel and blister packing machine ● Facility with Automatic Inspection machine will be preferred Expected Quality standard is compliance of WHO GMP. We expect long term business association.

Interested parties can send Site Master file along with list of manufacturing and testing equipments etc., within 7 days on

Email id: info@healthcarecorpcom.com

March 1-15, 2013

www.expresspharmaonline.com

EXPRESS PHARMA

61

62

EXPRESS PHARMA

www.expresspharmaonline.com

March 1-15, 2013

P|H|A|R|M|A| L|I|F|E

NUPUR DUBE Senior Manager, Human Resources, Karmic Life Sciences

Departments like quality assurance and human resource are completely managed by female employees. Core departments like business development, clinical operations, data management and medical affairs are either led by woman leaders or have female employees significantly outnumber their male counterparts

March 1-15, 2013

icture this: Close to one billion women are to enter the workforce in the next decade. The figure revealed in a survey on women in the workplace across 128 countries late last year by global management and strategy consultancy firm Booz and Company only emphasises that countries and industries world over cannot afford to ignore over 50 per cent of their talent pool, which happens to be none other than women.

It is only when organisations learn to tap the potential of their women employees and leaders, that they can see higher revenues and also contribute to economic growth of their country.

Gender equality and empowerment of women has a direct correlation with GDP growth, literacy rates and infant mortality rates.

P

Inching towards an equal footing Norway tops the list of countries when it comes to representation of women in business. It requires at least 40 per cent of board members in publicly listed companies to be women, a figure Spain has proposed within eight years. The Netherlands and France have also passed legislation.

The British Government aims to have women on at least 25 per cent of company boards by 2015. India, with pronounced gender disparity, still has a long way to catch up when it comes to economic participation of women. Factors such as safe working conditions, basic social security, existing disincentives including discrimination, cultural attitudes, taxation policies, and perhaps most importantly, competing family responsibilities pose themselves as impeding obstacles.

However, in the case of the Indian pharmaceutical industry, the scenario is much better with women at the helm of leadership positions at Biocon, Piramal Healthcare, Avesthagen to name a few. In contrast, there are no women heading major pharma companies in Europe and the US. It is also interesting to see how others are shaping up to ensure greater gender diversity to pave the way forward.

Quintiles India, a Contract Research Organization (CRO) is taking just the right steps in this

W

‘Improving the gender balance in the work place is a necessary step for India’s sustainable development’ What are the gaps in the current policies of the corporate sector as far as women's involvement in the workplace is concerned?

Despite being the second fastest growing economy in the world, gender disparities have remained deep and persistent in India. The UN Gender Inequality Index has ranked India below several sub-Saharan African countries. Gender disparities are even more pronounced in economic participation and women’s business conditions in India. A 2011 Global Gender Gap report scored women’s economic participation and opportunity in India being worse than 95 per cent of all countries in the sample.

Improving the gender balance in the work place is a necessary step for India’s sustainable development and its achievement of stabilised economic growth and gender equality. The participation of women in the workforce, the quality of work allotted to them and their contribution to the GDP are indicators of the extent to which women are mainstreamed into the economy. On all these parameters women in India currently fare worse than men, and one of India’s biggest challenges is to bridge this inequality and ensure that growth is inclusive.

Global Compact Network, UN Women and CARE India is currently working on a research report that aims to assess the

INTERVIEW status of women in the corporate sector to develop tools and strategies to advance gender equality and women’s empowerment in the workplace. The research will cover a few themes from gender equality in the workplace to tracking gender equality in the supply chain and community at the company level. Research results and recommendations will be shared during the last quarter of 2013.

Anne F Stenhammer Regional Programme DirectorUN Women, South Asia Regional Office

Sexual harassment and gender bias remain contentious issues globally. How can companies ensure these are addressed?

In countries where legal framework to protect women from sexual harassment at the work place already exists, companies should ensure compliance by aligning their policies to the law of the land. There should be laid out mechanism to ensure the implementation and monitoring of such policies. Additionally it is important to create a culture of non-discrimination and gender equality at the workplace. This can be done through regular capacity development and awareness generation across different levels of the company. In addition, CSR initiatives should also be compliant with nondiscrimination and gender equality mandates.

Companies could initiate projects that address issues of sexual harassment and gender bias within the communities.

In India, there is already a legal and policy framework for addressing sexual harassment at the workplace. Vishakha guidelines already exist on sexual harassment at the workplace, and recently a Bill on sexual harassment at workplace has been passed by the Lok Sabha. Effective implementation of these guidelines and laws are of utmost importance for ensuring safety and security of women at the workplace. In addition, Ministry of Corporate Affairs has launched National Voluntary Guidelines for Responsible Business in which Principle 5 (of 9) guides businesses to “respect and promote human rights” Within the seven principles, WEPs #2 and #3 clearly help set guidelines that reflect on sexual harassment and gender bias within the workplace. It is also recommended that organisations have a Code of Conduct for the workplace and in addition, recommend that the SecretaryGeneral’s Bulletin’s on the prohibition of discrimination, harassment, including sexual harassment and abuse of authority and the UNDP’s Policy of Workplace Harassment and Abuse of Authority be utilised as guidelines to implement similar policies. Besides this, corporates must also wake up to the reality of the safety and security of women in public spaces and support interventions in this area, ensuring women’s safety and security.

www.expresspharmaonline.com

MEN’S DAY SPECIAL

direction. The company was conferred with the Highest Percentage of Women Employer-ITES award by the Software Technology Parks of India (STPI), Government of India and the Department of IT, BT & ST, Government of Karnataka for the year 2011-12. With a ratio of female to male employees of 13:12, it is setting a benchmark for others towards creating a conducive work environment for women.

Pitches in Trupti Talati, Senior Director, Human Resources, Quintiles India, “This ratio is consistent across business units whether it is one that predominantly hires medical and scientific talent or technology talent or general management talent. This in itself is indicative of the fact that it is the overall womenfriendly environment enabled by favourable policies that attracts women to Quintiles.” The company has also made it to the World’s Best Multinational Workplaces by the Great Place to Work Institute a few years back.

Close on its heels is Karmic Life sciences, led by Nidhi Saxena, Chief Executive Officer and President of the company who was awarded the First Generation Woman Entrepreneur at the Fifth Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2012. The organisation has succeeded to maintain near equilibrium in headcount of male and female employees with a ratio of 7:8.

“It is noteworthy to mention that departments like quality assurance and human resource are completely managed by female employees. Core departments like business development, clinical operations, data management and medical affairs are either led by woman leaders or have female employees significantly outnumber their male counterparts,” corroborates Nupur Dube, Senior Manager Human Resources, Karmic Life Sciences.

By successfully managing to strike a healthy balance of workforce and gender equilibrium, the organisation has carved a culture that not only accepts woman leaders at key positions but also values a high performance driven and merit EXPRESS PHARMA

63

P|H|A|R|M|A| L|I|F|E

oriented environment that is free from all gender biases, she adds.

With 1000 women employees as a part of its workforce, Biocon is positioning itself as a preferable employer for women, most notably scientists. “We are proud that 30 per cent of our scientists are women who feel empowered and enabled to pursue their career ambitions at Biocon,” Ravi C Dasgupta, Group Head HR, Biocon.

Medtronic India also prides itself in having reached a gender diversity of 16 per cent. Echoes Titus Arnold, Head HR, Medtronic, “We are looking at building a pipeline of women employees by aiming for atleast one woman in every leading function or department. The mission is to make sure there are enough women in the India leadership team at the senior management.”

Flexi work and work life balance So how do organisations manage to retain women employees and better train and advance them to middle and senior management? Of course, it has to do with company policies. Pfizer, a research—based pharma firm has a supplier diversity programme with women and minorities, more than five child care facilities, a phaseback programme for new moms returning to work, and flexi time. Often the need for women-friendly policies grows over time, after women have surpassed the initial stages of their career where learning on the job is the main focus.

Flexibility becomes crucial for them as they juggle both work and home, elaborates Hussain Tinwala, General Manager, Teamlease services. However, about flexitime, he feels there is still a nascent concept in the industry, although it is gradually finding its way. There has been a shift in employers willing to recruit more women in the sales and offering them flexible timings and local outreach within 8-10 kms of their area so as to encourage their participation and retention as well.

More than men it is women who strive for worklife balance, asserts Rebecca Shambaugh in her book, It’s Not a Glass Ceiling, It’s A Sticky Floor, which provides

64

EXPRESS PHARMA

W

MEN’S DAY SPECIAL

TITUS ARNOLD

RAVI C DASGUPTA

TRUPTI TALATI

Group Head HR Biocon

Senior Director Human Resources Quintiles India

Director Human Resources-South Asia Medtronic

We are proud that 30 per cent of our scientists are women who feel empowered and enabled to pursue their career ambitions at Biocon

Women want to work for organisations that promote a culture where they are valued and recognised. Benefits and programmes, although important, are just an expression of this culture

We are looking at building a pipeline of women employees by aiming for atleast one woman in every leading function or department

insight and advice for women seeking to advance their careers. However, they are also the ones pushing the boundaries for companies to think out of the box and come up with ways and means for more engagement at work while not compromising their personal lives. Both Quintiles and Karmic Lifesciences offer flexible working options including option to work from home, part time employment options as well as flexible working hours. At Quintiles,

women who relocate to areas where the company doesn’t have an office are allowed to work from home as well.

“Both flexitime and telecommuting offer women a great opportunity to work without a break and advance their careers in a level playing field. From a corporate standpoint, it makes for a happier and more contented employee which undoubtedly will reflect in productivity improvement,” exhorts Talati.

Women on shifts are pro-

vided with transport to ensure their safety and security. Safety measures are incorporated in the company policy at Karmic with periodic safety awareness trainings/ workshops facilitated by the human resource department to enable a secured working environment. At Biocon, the vehicles are constantly monitored with follow up phone calls enquiring the safe drop of women employees. Quintiles also offers Healthy U Healthy

Women’s Empowerment Principles(WEPs) he Women's Empowerment Principles offer seven steps to guide business on how to empower women in the workplace, marketplace and community. Subtitled Equality Means Business, the Principles emphasise the business case for corporate action to promote gender equality and women's empowerment and are informed by real-life business practices and input gathered from across the globe. The WEPs are the result of collaboration between the United Nations Entity for Gender Equality and the Empowerment of Women (UN Women) and the United Nations Global Compact (UNGC). The Principles were developed through a year-long international multi-stakeholder consultation process and launched to the global community on International Women‘s Day 2010 (8 March). These include: 1) Leadership promotes gender equality 2) Equal opportunity, inclusion and non-discrimination 3) Health, safety and Freedom from violence 4) Education and Training 5) Enterprise Development, Supply Chain and Marketing Practices 6) Community Leadership and Engagement 7) Transparency, Measuring and Reporting Globally 466 companies are signatories to the WEPs with six in India: HCL, Infosys, WIPRO, Paharpur Business Center, Coca Cola Company, Jindal Stainless Steel.

T

www.expresspharmaonline.com

March 1-15, 2013

P|H|A|R|M|A| L|I|F|E

Q, an internal employee wellness programme which has four components including a physical activity reimbursement programme, an online health and well-being assessment, a dedicated wellness website HealthyUHealthyQ.com and a tobacco free workplace.

A consideration for women also goes a long way.

Arnold cites the case of a woman Product Manager at Medtronic who had to travel to Kolkata for work. Sensing her requirements, the company arranged for her family to accompany her for the visit. Such little gestures go a long way. He sums it up best when he says, “Women do not want charity, they want support.” However, he is also quick to add that flexible work hours would apply more to those who are not in the frontline.

The road ahead Most women tend to either take a break in their careers or leave it altogether post motherhood and hence ensuring that their childcare needs are addressed is also important. In the US, Childcare is a big issue for

W

women in their career progression with those living hand-to-mouth in lowwaged jobs having 41 per cent of their salaries taken over by childcare costs. In India, while the ITES sector has been fairly proactive to have child care facilities with company premises, the concept is yet nascent in the pharma sector. It is imperative then that companies take cognizance to the fact that this needs to be

MEN’S DAY SPECIAL

Employees are allowed to go on leave without pay thereafter, which gives additional time with their child. The company’s mediclaim policy covers children as soon as they are born. To further support the return of women to work, Biocon offers a creche facility managed by professionals.

When asked whether women employees respond well to a more generous childcare rather than a better

IN CASE OF INDIAN PHARMACEUTICAL INDUSTRY,THE SCENARIO IS MUCH BETTER WITH WOMEN AT THE HELM OF LEADERSHIP POSITIONS AT BIOCON, PIRAMAL HEALTHCARE, AVESTHAGEN TO NAME A FEW addressed. Quintiles also provides an extended paid maternity leave of one month in addition to the statutory three months. New mothers are also offered an option to avail accrued privilege leave in addition to the above. This allows them to be with their new born child for close to six months.

maternity leave, Dube responds, “No single initiative can be appointed as a self-sufficient tool to guarantee retention of woman employees. In today’s highly demanding, dynamic and challenging business scenarios it becomes increasingly essential for the human resource department to

strike a balance while carving its initiatives which must be executed after a thorough culture audit and also ‘continuously innovate and renovate’ relevant engagement initiatives that facilitate both high performing teams and engaged woman employees”.

Mentoring and having role models to emulate also helps. Unless one has a mentor who can guide and advise at crucial times forging the road ahead can be a bit tricky. Having networks either social or professional that address issues women face at work could also help them vent their problems.

Clear and stringent sexual harassment policies would also go a long way in affirming womens’ confidence and faith in their organisation and increasing their participation in the labour force.

Ultimately it all boils down to company work culture.

Talati puts it best, “Women want to work for organisations that promote a culture where they are valued and recognised. Benefits and programmes, although important, are just an expression of this culture.” shalini.g@expressindia.com

APPOINTMENT Bhasker Iyer named Divisional Vice President, India for Abbott’s Pharmaceuticals Business Will identify further opportunities to expand access to Abbott’s broad portfolio of quality products in India hasker Iyer has been named as the Divisional Vice President, India Commercial Operations, Abbott E s t a b l i s h e d Pharmaceuticals, effective February 18, 2013. Iyer will report to Mike Warmuth, Executive Vice President, Established Pharmaceuticals Division, Abbott.

Iyer brings over 30 years pharmaceutical industry experience in sales, marketing, business development and general management to this new role at Abbott. He has worked for a number of pharma companies, most recently at Wockhardt where he held the position of President India and Emerging Markets.

Abbott’s pharma busi-

B

March 1-15, 2013

ness in India - Abbott India, Abbott Healthcare Solutions www.expresspharmaonline.com

and Abbott True Care, will report into this newly estab-

lished position. Iyer will work with the business leadership teams to identify further opportunities to expand access to Abbott’s broad portfolio of quality products in India which are adapted to the needs of the Indian population.

Announcing the appointment, Mike Warmuth said, “We welcome the addition of Iyer to our Abbott leadership team in India. The establishment of this position reinforces the focus of the company’s strategy in India to bring quality medicines to patients that make a difference in their lives and to ensure patients and the healthcare community has access to these medicines.”

EP News Bureau - Mumbai EXPRESS PHARMA

65

P|H|A|R|M|A| L|I|F|E

W

MEN’S DAY SPECIAL

JOB TRENDS 2013 brings a positive hope for pharma sector employees The index value at 1381 is the highest value in the last one year ome good news in store for job seekers as hiring activity for the pharmaceutical sector moved up by four per cent in January 2013

S

cent more than the same time a year before. The index value at 1381 is the highest value in the last one year.

petitors in every sphere. Info Edge was the first internet Company to list in India. The site enjoys a traffic share of around 61 per cent as per the Sept

Access, and Response Management tools and its services include Job Postings, and recruiter branding solutions on the site. The site has a data-

The Naukri job speak index for the pharma sector is a monthly report that indicates hiring trends across industry sectors, geographies and functional areas when compared to December 2012.

This upward movement in the Naukri Job Speak index has been witnessed consecutively for the past three months. Also what is interesting to note that hiring activity for the sector in January 2012 is 16 per

About Naukri.com Naukri.com, India’s No 1 job site and the flagship brand of Info Edge revolutionized the concept of recruitment in India. Since its inception in 1997, Naukri.com has seen continued growth while outperforming its com-

Comscore data.

Naukri.com is a recruitment platform that provides hiring-related services to corporates/ recruiters, placement agencies and to job seekers in India and overseas. It offers multiple products like Resume Database

base of over 29 million resumes and has serviced over 46000 clients in FY2012. The company has over 2000 people operating through 48 offices in 31 cities in India and overseas offices in Dubai, Abu Dhabi, Riyadh and Bahrain.

Jobs from Naukri.com Asst. Manager - PP & QM (sap) Company: Exp: Location: Job Id:

Famy Care 3-5 Mumbai 121212003158

Associate - Third Party Procurement Company: Exp: Location: Job Id:

Nutrition Field Officer Company: Exp: Location: Job Id:

Ayurwin Pharma 1-4 Bengaluru/Bangalore 050213001521

Product Specialist - Derma Company: Exp: Location: Job Id:

Area Business Manager Company: Exp: Location: Job Id:

Morepen Laboratories 4-8 Delhi 050213000804

Hiring Biostatistician for Hyderabad Company:

inVentiv International Pharma Services 3-8 Hyderabad / Secunderabad 050213000667

Exp: Location: Job Id:

VWR Lab Product 0-2 Coimbatore 250812000724

Biocon 2-6 Mumbai 020113001686

Product Manager - PMT Company: Exp: Location: Job Id:

Torrent Pharmaceuticals 5-10 Ahmedabad 181212000504

Manager - Engineering & Services Company: Exp: Location: Job Id:

Mangalam Drugs & Organics 10-12 Dadra & Nagar Haveli 050113001720

Sr Manager - Cell Culture

Accountant & Computer Operator Company: Exp: Location: Job Id:

Healthy Life Pharma 5-10 Mumbai Suburbs 030511000976

Manager OF Accounting Finance Company: Exp: Location: Job Id:

PRA International 5-7 Mumbai 040213004027

Clinical Data Management Trainee Company: Exp: Location: Job Id:

Andronovo Labs 0-3 Hyderabad / Secunderabad 040213003987

GM - Production API - Sanga Reddy Company: Exp: Location: Job Id:

Hetero Drugs 14-22 Hyderabad / Secunderabad 040213003249

Manager - Regulatory Affairs

Sr Software Engineer Company: Exp: Location: Job Id:

66

EXPRESS PHARMA

Medisurge Technologies 4-6 Surat 050213000602

Company: Exp: Location: Job Id:

Mylan Pharmaceuticals 6-10 Hyderabad / Secunderabad 250113003557

www.expresspharmaonline.com

Company: Exp: Location: Job Id:

Symbiotec Pharmalab 9-11 Indore 131212002470

March 1-15, 2013

REGD.WITH RNI NO.MAHENG/2005/21398 REGD.NO.MH/MR/SOUTH-77/2013-15, PUBLISHED ON 5TH & 20TH EVERY FORTNIGHLY & POSTED 6-7-8 & 21-22-23 OF EVERY FORTNIGHLY. AT IND.EXP.PSO.